Inhibitors of post-proline cleaving proteases

ABSTRACT

Novel compounds that are inhibitors of one or most post-proline cleaving proteases, e.g. dipeptidyl peptidase IV, according to general formula (1). R 1  is H or CN, X 1  is O, S, CH 2 , CHF, CF 2 , CH(CH 3 ), C(CH 3 ) 2  or CH(CN), and b is 1 or 2. G 1  is H or a group according to the formula —CH 2 —X 2 —(CH 2 ) a -G 3  and G 2  is H or a group according to the formula —CH 2 —(CH 2 9 a -G 3 , provided that one of G 1  and G 2  is H and the other is not H. X 2  is O, S, or CH 2 , and a is 0, 1 or 2, provided that when a is 1 then X 2  is CH 2 . G 3  is a group according to one of general formulae 2-4, where the variables have meaning given in the description. The compounds are useful in the treatment of i.a. type 2 diabetes and impaired glucose tolerance.

The present invention relates to novel compounds that are inhibitors of post-proline aminopeptidases. The compounds are useful as antiproliferative agents and in the treatment of, inter alia, type 2 diabetes and impaired glucose tolerance.

BACKGROUND

The enzyme dipeptidyl peptidase IV, herein abbreviated DP-IV (and elsewhere as DAP-IV or DPP-IV) and also known by the classification EC.3.4.14.5, is a serine protease that cleaves the N-terminal dipeptide from peptides that begin with the sequence H-Xaa-Pro (where Xaa is any amino acid, although preferably a lipophilic one, and Pro is proline). It will also accept as substrates peptides that begin with the sequence H-Xaa-Ala (where Ala is alanine). DP-IV was first identified as a membrane-bound protein. More recently a soluble form has been identified.

Initial interest in DP-IV focussed on its role in the activation of T lymphocytes. DP-IV is identical to the T cell protein CD26. It was proposed that inhibitors of DP-IV would be capable of modulating T cell responsiveness, and so could be developed as novel immunomodulators. It was further suggested that CD26 was a necessary co-receptor for HIV, and thus that DP-IV inhibitors could be useful in the treatment of AIDS.

Attention was given to the role of DP-IV outside the immune system. It was recognised that DP-IV has a key role in the degradation of several peptide hormones, including growth hormone releasing hormone (GHRH) and glucagon-like peptide-1 and -2 (GLP-1 and GLP-2). Since GLP-1 is known to have a potentiating effect on the action of insulin in the control of post-prandial blood glucose levels it is clear that DP-IV inhibitors might also be usefully employed in the treatment of type II diabetes and impaired glucose tolerance. At least two DP-IV inhibitors are currently undergoing clinical trials to explore this possibility.

Several groups have disclosed inhibitors of DP-IV. While some leads have been found from random screening programs, the majority of the work in this field has been directed towards the investigation of substrate analogues. Inhibitors of DP-IV that are substrate analogues are disclosed in, for example, U.S. Pat. No. 5,462,928, U.S. Pat. No. 5,543,396, WO95/15309 (equivalent to U.S. Pat. No. 5,939,560 and EP 0731789), WO98/19998 (equivalent to U.S. Pat. No. 6,011,155), WO99/46272 and WO99/61431.

More recently a number of proteins have been found that share some of the enzymatic properties of DP-IV. Some, such as FAP and DPP-8, have sequence homology with DP-IV, while others, such as QPP, have no such homology but nevertheless mimic the aminodipeptidase activity of DP-IV. The physiological function of these newer proteases is still being investigated. FAP has been implicated in invasive processes such as cancer metastasis and endometriosis, and QPP appears to be involved in immune-cell apoptosis. It is also possible that some of these proteases share a common function. This redundancy would allow continuing normal physiological function in the event of a failure in the expression or function of one of the proteases.

In order to further define the roles of these newer proteases it is important to have the tools to manipulate selectively each one or the whole class. Therefore there exists a need for specific and potent inhibitors of each of these proteases, and also for potent non-specific inhibitors of the class of post-proline cleaving aminodipeptidases.

SUMMARY OF THE INVENTION

We disclose herein a series of novel compounds that are inhibitors of one or more post-proline cleaving proteases, and specifically compounds according to general formula 1.

In general formula 1, R¹ is H or CN, X¹ is O, S, CH₂, CHF, CF₂, CH(CH₃), C(CH₃)₂ or CH(CN), and b is 1 or 2. G¹ is H or a group according to the formula —CH₂—X²—(CH₂)_(a)-G³ and G² is H or a group according to the formula —CH₂ (CH₂)_(a)-G³, provided that one of G¹ and G² is H and the other is not H. X² is O, S or CH₂, and a is 0, 1 or 2, provided that when a is 1 then X² is CH₂. G³ is a group according to one of general formulae 2-4.

X³, X⁴ and X⁵ are either nitrogen N or CH, provided that at least two of X³, X⁴ and X⁵ are N. X⁶ is either O or NH. R² is either H or alkyl. R³ is selected from H, Cl, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂. R⁴, R⁵, R⁶, R⁷ and R⁸ are selected from H, Br, Cl, F, CF₃, alkyl, acyl, OH, O-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NO₂, NH-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂ and CN. X⁷ is CH₂, O, S or NH. R⁹ is either H or alkyl. R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ are selected from H, Br, Cl, F, CF₃, alkyl, acyl, OH, O-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NO₂, NH-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂ and CN. R¹⁵ and R¹⁶ are each independently H, alkyl, alkenyl, polyfluoroalkyl, aralkyl, aryl or CH₂-L-R⁷, where L is a covalent bond, CH═CH, C≡C or —C₆H₄—, and R¹⁷ is H, alkyl or aryl, or R¹⁵ and R¹⁶ together are a group according to one of general formulae 5-7.

R¹⁸ is H, alkyl, aryl, OH, O-alkyl, NH₂, NH-alkyl or N(alkyl)₂, and R¹⁹ is H, alkyl, aryl, F, Cl, Br, CF₃, OH, O-alkyl, NH₂, NH-alkyl or N(alkyl)₂. The integers d and e are 0, 1, 2 or 3 such that d+e is 3, 4 or 5, and f is 1, 2 or 3. When R¹⁵ and R¹⁶ are both H then X¹ may not be S or CH₂ if b is 1.

Preferred compositions are inhibitors of non-membrane associated post-proline cleaving proteases. The most preferred compositions are selective for non-membrane associated proteases (e.g. for example inhibitors of one or more of QPP, DPP-8 and/or DPP-9).

DETAILED DESCRIPTION OF THE INVENTION

In a first aspect, the present invention relates to a series of novel α-amino acyl derivatives of saturated nitrogen-containing heterocycles according to general formula 1.

In general formula 1, the group R¹ is either a hydrogen atom H or a nitrile group CN. The group X¹ is selected from an oxygen atom 0, a sulphur atom S, a methylene group CH₂, a monofluoromethylene group CHF, a difluoromethylene group CF₂, an ethylidene group CH(CH₃), a 2-propylidene group C(CH₃)₂ and a cyanomethylene group CH(CN). The integer b is either 1 or 2, such that the nitrogen-containing ring has 5 or 6 members.

The group G¹ is either H or a group according to the formula —CH₂—X²—(CH₂)_(a)-G³ and the group G² is either H or a group according to the formula —CH₂—(CH₂)_(a)-G³, provided that one of G¹ and G² is H and the other is not H. The group X² is selected from O, S and CH₂. The integer a is 0, 1 or 2, provided that when a is 1 then X² is CH₂.

The group G³ is selected from a group according to general formula 2, a group according to general formula 3 and a group according to general formula 4.

In general formula 2, the groups X³, X⁴ and X⁵ are selected from nitrogen N and methine CH, provided that at least two of X³, X⁴ and X⁵ are nitrogen. Preferably X³, X⁴ and X⁵ are all nitrogen. The group X⁶ is selected from O and NH. R² is selected from H and alkyl. R³ is selected from H, Cl, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂. R⁴, R⁵, R⁶, R⁷ and R⁸ are independently selected from H, Br, Cl, F, CF₃, alkyl, acyl, OH, O-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NO₂, NH-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂ and CN.

In general formula 3, the group X⁷ is selected from CH₂, O, S and NH. R⁹ is selected from H and alkyl. R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ are independently selected from H, Br, Cl, F, CF₃, alkyl, acyl, OH, O-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NO₂, NH-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂ and CN.

In general formula 4, R¹⁵ and R¹⁶ are each independently selected from H, alkyl, alkenyl, polyfluoroalkyl, aralkyl, aryl and CH₂-L-R⁷, where L is selected from a covalent bond, CH═CH, C≡C and —C₆H₄— and R¹⁷ is selected from H, alkyl and aryl, or R¹⁵ and R¹⁶ together are a group selected from general formula 5, general formula 6 and general formula 7.

In these general formulae, the group R¹⁸ is selected from H, alkyl, aryl, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂, and the group R¹⁹ is selected from H, alkyl, aryl, F, Cl, Br, CF₃, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂. The integers d and e are selected from 0, 1, 2 and 3 such that d+e is 3, 4 or 5, and the integer f is selected from 1, 2 and 3.

When R¹⁵ and R¹⁶ are both H then X¹ may not be S or CH₂ if b is 1.

The term alkyl, as used herein, denotes saturated hydrocarbon groups with between 1 and 10 carbon atoms, including straight-chain, branched and mono- and polycycloalkyl groups, such as methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, cyclopentyl, cyclohexylmethyl, 2-cyclohexyl-2-propyl, bicyclo[2.2.2]octyl and the like.

The term alkenyl, as used herein, denotes monounsaturated hydrocarbon groups with between 2 and 10 carbon atoms, including straight-chain, branched and mono- and polycycloalkenyl groups, such as vinyl, allyl, methallyl, cyclohex-3-enyl and the like.

The term aryl, as used herein, denotes monocyclic and fused bicyclic aromatic groups, including carbocyclic groups, such as phenyl and naphthyl, and heteroaryl groups with up to three heteroatoms selected from nitrogen, oxygen and sulphur, such as pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isothiazolyl, pyridyl, pyrimidinyl, indolyl, quinolinyl and the like. Unless otherwise specified, aryl groups may optionally be substituted with up to three groups independently selected from alkyl, OH, O-alkyl, Cl, F, Br, NH₂, NH-alkyl, N(alkyl)₂, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, NO₂ and CN.

The term aralkyl, as used herein, denotes alkyl groups that are substituted by, or fused to, one or more aryl groups, including benzyl, phenethyl, indanyl, fluorenyl and the like.

The term acyl, as used herein, denotes a group selected from H—CO, alkyl-CO, aryl-CO and aralkyl-CO, including formyl, acetyl, benzoyl, phenylacetyl and the like.

The term polyfluoroalkyl, as used herein, denotes an alkyl group wherein all the hydrogen atoms on one or more of the carbon atoms are replaced by fluorine atoms, including trifluoromethyl, 2,2,2-trifluoroethyl and the like.

In one preferred embodiment of the invention R¹ is H.

In another preferred embodiment of the invention R¹ is CN.

In another preferred embodiment of the invention X¹ is CH₂.

In another preferred embodiment of the invention X¹ is S.

In another preferred embodiment of the invention b is 1.

In another preferred embodiment of the invention b is 2.

In another preferred embodiment of the invention a is 0.

In another preferred embodiment of the invention a is 0 and X² is CH₂.

In another preferred embodiment of the invention a is 1.

In another preferred embodiment of the invention a is 1 and X² is CH₂.

In another preferred embodiment of the invention a is 2 and X² is CH₂.

In another preferred embodiment of the invention the compound is a compound according to general formula 8.

In another preferred embodiment of the invention the compound is a compound according to general formula 9.

In another preferred embodiment of the invention the compound is a compound according to general formula 10.

In another preferred embodiment of the invention the compound is a compound according to general formula 11.

In another preferred embodiment of the invention the compound is a compound according to general formula 12.

In another preferred embodiment of the invention the compound is a compound according to general formula 13.

It will be recognised that certain of the compounds within the scope of the present invention are capable of forming salts with suitable acids or bases. To the extent that such salts are pharmaceutically acceptable they are included within the scope of this invention.

It will further be recognised that certain of the compounds within the scope of the present invention are capable of existing as optical isomers, such as enantiomers and diastereomers. All such optical isomers and mixtures thereof, including but not limited to racemates, are included within the scope of the invention.

The compounds of the present invention are inhibitors of post-proline cleaving proteases such as DPP-IV, QPP, FAP, DPP-8 (DPRP-1) and DPP-9 (DPRP-2). As such they may be useful in the treatment of diseases in which dysregulation of these enzymes or their endogenous substrates plays a role or the disease is ameliorated by inhibition of such enzymes. Accordingly, in further aspects, the present invention provides for the use of compounds according to the present invention in the preparation of pharmaceutical compositions, and for the use of such compositions a therapeutic agents.

Preferred compositions which are inhibitors for QPP may have G²=H, b=1 or 2 and/or a=0 or 1. Further preferred compositions having b=2 include G1 groups having a=0 or 1 and X² is CH₂ Further preferred compositions having b=2 have X¹═CH₂ or S, for example Example 38 of Table 2. Further preferred compositions having b=1 include G1 groups having a=0 or 1 and X² is CH₂. Further preferred compositions having b=1 have X¹═S or CH₂ or CF₂, for example, Example 42 of Table 2.

The compounds of the present invention can be prepared by methods generally known in the art and illustrated in the following non-limiting examples.

EXAMPLES Example 1 (2S)-1-[N^(ω),N^(ω)-(Dicinnamyl)-L-lysinyl]pyrrolidine-2-carbonitrile dihydrochloride

A. (N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl)-L-prolinamide

N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysine (5 g, 10.7 mmol) was dissolved in CH₂Cl₂ (100 mL). The solution was cooled to 0° C., L-prolinamide (1.78 g, 11.7 mmol) and PYBOP® (6.7 g, 12.8 mmol) were added, and the pH adjusted to pH9 with triethylamine. After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (200 mL). The solution was washed with 0.3M KHSO₄ (2×50 mL), sat. NaHCO₃ (2×50 mL), water (2×50 mL) and brine (1×50 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 2% methanol, 98% chloroform) to give a colourless oil identified as (N^(α)-(tert-butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl)-L-prolinamide (4.05 g, 7.2 mmol, 67%).

B. (2S)-1-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl)pyrrolidine-2-carbonitrile

(N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl)-L-prolinamide (3.95 g, 7.02 mmol) was dissolved in dry THF (100 mL). The solution was cooled to 0° C., triethylamine (1.4 g, 14 mmol) was added followed by the slow addition of trifluoroacetic anhydride (2.97 g, 14.1 mmol). The pH was adjusted to pH9 with triethylamine. After 30 min the reaction mixture was diluted with ethyl acetate (100 mL), washed with water (1×50 mL) and brine (1×50 mL), dried (Na₂SO₄) and evaporated in vacuo to give an orange oil. The residue was purified by flash chromatography on silica gel (eluant: 60% pet ether, 40% ethyl acetate) to give a colourless oil identified as (2S)-1-(N^(α)-(tert-butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl)pyrrolidine-2-carbonitrile (3.3 g, 6.11 mmol, 87%).

C. (2S)-1-(N^(α)-(tert-Butyloxycarbonyl)-L-lysinyl)pyrrolidine-2-carbonitrile

(2S)-1-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl)-pyrrolidine-2-carbonitrile (3.1 g, 5.7 mmol) was dissolved in THF (80 mL). Diethylamine (20 mL) was added. After 2 h at room temperature the solvent was removed in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a colourless oil identified as (2S)-1-(N^(α)-(tert-butyloxycarbonyl)-L-lysinyl)pyrrolidine-2-carbonitrile (1.63 g, 5.03 mmol, 89%).

D. (2S)-1-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω),N^(ω)-(dicinnamyl)-L-lysinyl)pyrrolidine-2-carbonitrile

(2S)-1-(N^(α)-(tert-Butyloxycarbonyl)-L-lysinyl)pyrrolidine-2-carbonitrile (100 mg, 0.31 mmol) was dissolved in methanol (25 mL). To this solution was added trans-cinnamaldehyde (170 mg, 1.18 mmol). After 30 mins sodium triacetoxyborohydride (330 mg, 1.56 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 2% methanol, 98% chloroform) to give a colourless oil identified as (2S)-1-(N^(α)-(tert-butyloxycarbonyl)-N^(ω),N^(ω)-(dicinnamyl)-L-lysinyl)pyrrolidine-2-carbonitrile (38 mg, 0.068 mmol, 11%). Further elution with 9% methanol, 90% chloroform and 1% acetic acid gave a colourless oil identified as (2S)-1-(N^(α)-(tert-butyloxycarbonyl)-N^(ω)-(cinnamyl)-L-lysinyl)pyrrolidine-2-carbonitrile (32 mg, 0.073 mmol, 12%).

E. (2S)-1-[N^(ω),N^(ω)-(Dicinnamyl)-L-lysinyl]pyrrolidine-2-carbonitrile dihydrochloride

(2S)-1-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω),N^(ω)-(dicinnamyl)-L-lysinyl)pyrrolidine-2-carbonitrile (32 mg, 0.057 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as (2S)-1-[N^(ω),N^(ω)-(dicinnamyl)-L-lysinyl]pyrrolidine-2-carbonitrile dihydrochloride (37 mg, 0.053 mmol, 93%).

[M+H]⁺=457.3

¹H NMR (CD₃OD): δ 1.35-1.55 (2H, m), 1.75-2.00 (2H, m), 2.05-2.23 (6H, m), 3.10-3.29 (4H, m), 3.61-3.68 (2H, m), 4.00-4.03 (4H, m), 4.20-4.30 (1H, m), 4.82-4.93 (1H, m), 6.34-6.39 (2H, m), 6.94 (2H, d, J=5.8 Hz), 7.31-7.37 (6H, m), 7.39-7.53 (4H, m) ppm.

Example 2 (2S)-1-[N^(ω)-(Cinnamyl)-L-lysinyl]pyrrolidine-2-carbonitrile dihydrochloride

A. (2S)-1-[N^(ω)-(Cinnamyl)-L-lysinyl]pyrrolidine-2-carbonitrile dihydrochloride

(2S)-1-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(cinnamyl)-L-lysinyl)pyrrolidine-2-carbonitrile (32 mg, 0.057 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as (2S)-1-[N^(α)-(cinnamyl)-L-lysinyl]pyrrolidine-2-carbonitrile dihydrochloride (37 mg, 0.053 mmol, 93%).

[M+H]⁺=341.5

¹H NMR (CD₃OD): δ 1.29-1.55 (2H, m), 1.72-1.80 (2H, m), 1.90-2.11 (2H, m), 2.16-2.29 (6H, m), 3.02-3.09 (2H, m), 3.65-3.69 (2H, m), 3.78-3.82 (2H, m), 4.23-4.27 (1H, m), 4.81-4.82 (1H, m), 4.91-4.99 (1H, m), 6.21-6.32 (1H, m), 6.86 (1H, d, J=6.1 Hz), 7.26-7.35 (3H, m), 7.37-7.40 (2H, m) ppm.

Example 3 (2S)-1-[N^(ω),N^(ω)-(Dicinnamyl)-L-ornithinyl]pyrrolidine-2-carbonitrile dihydrochloride

A. (2S)-(N^(α)-(tert-Butyloxycarbonyl)-L-ornithyl)pyrrolidine-2-carbonitrile

(2S)-1-(N^(α)-(tert-Butyloxycarbonyl)-L-ornithyl)pyrrolidine-2-carbonitrile was prepared by the method described for the lysine derivative in Example 1.

B. (2S)-(N-(tert-Butyloxycarbonyl)-N^(ω),N^(ω)-(dicinnamyl)-L-ornithinyl)pyrrolidine-2-carbonitrile

(2S)-1-(N^(α)-(tert-Butyloxycarbonyl)-L-ornithinyl)pyrrolidine-2-carbonitrile (200 mg, 0.65 mmol) was dissolved in methanol (25 mL). To this solution was added trans-cinnamaldehyde (180 mg, 1.25 mmol). After 30 mins sodium triacetoxyborohydride (343 mg, 1.63 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography (eluant: 2% methanol, 98% chloroform) to give a colourless oil identified as (2S)-1-(N^(α)-(tert-butyloxycarbonyl)-N^(ω),N^(ω)-(dicinnamyl)-L-ornithinyl)-pyrrolidine-2-carbonitrile (77 mg, 0.14 mmol, 22%). Further elution with 9% methanol, 90% chloroform and 1% acetic acid gave a colourless oil identified as (2S)-1-(N^(α)-(tert-butyloxycarbonyl)-N^(ω)-(cinnamyl)-L-ornithinyl)pyrrolidine-2-carbonitrile (78 mg, 0.18 mmol, 28%).

C. (2S)-1-[N^(ω),N^(ω)-(Dicinnamyl)-L-ornithinyl]pyrrolidine-2-carbonitrile dihydrochloride

(2S)-1-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω),N^(ω)-(dicinnamyl)-L-ornithinyl)pyrrolidine-2-carbonitrile (67 mg, 0.12 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as (2S)-1-[N^(ω),N^(ω)-(dicinnamyl)-L-ornithinyl]pyrrolidine-2-carbonitrile dihydrochloride (82 mg, 0.12 mmol, 100%).

[M+H]⁺=443.3

¹H NMR (CD₃OD): δ 1.98-2.12 (4H, m), 2.22-2.29 (4H, m), 3.27-3.31 (4H, m), 3.62-3.67 (2H, m), 3.96 (4H, d, J=7.5 Hz), 4.30-4.40 (1H, m), 4.80-4.83 (1H, m), 6.34-6.41 (2H, m), 6.96 (2H, d, J=15.6 Hz), 7.31-7.39 (6H, m), 7.49-7.53 (4H, m) ppm.

Example 4 (2S)-1-[N^(ω)-(Cinnamyl)-L-ornithinyl]pyrrolidine-2-carbonitrile dihydrochloride

A. (2S)-1-[N^(ω)-(Cinnamyl)-L-ornithinyl]pyrrolidine-2-carbonitrile dihydrochloride

(2S)-1-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(cinnamyl)-L-ornithinyl)pyrrolidine-2-carbonitrile (71 mg, 0.17 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as (2S)-1-[N^(ω)-(cinnamyl)-L-ornithinyl]pyrrolidine-2-carbonitrile dihydrochloride (91 mg, 0.16 mmol, 100%).

[M+H]⁺=327.5

¹H NMR (CD₃OD): δ 1.70-1.88 (2H, m), 1.97-2.01 (2H, m), 2.14-2.32 (4H, m), 3.08-3.13 (2H, m), 3.29-3.31 (3H, m), 3.68-3.71 (2H, m), 3.79-3.82 (2H, m), 4.29-4.31 (1H, m), 4.87-4.91 (1H, m), 6.29-6.31 (1H, m), 6.86 (1H, d, J=15.8 Hz), 7.29-7.30 (3H, m), 7.44-7.48 (2H, m) ppm.

Example 5 3-[N^(ω),N^(ω)-(Dicinnamyl)-L-lysinyl]thiazolidine dihydrochloride

A. 3-[N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]-thiazolidine

N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysine (2.73 g, 6 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 100 mL). To this solution at 0° C. were added 1-hydroxybenzotriazole hydrate (1.53 g, 10 mmol), water-soluble carbodiimide (1.34 g, 7 mmol), thiazolidine (1.28 g, 18 mmol) and N-methylmorpholine (1.0 g, 10 mmol). After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100 mL). The solution was washed with 0.3M KHSO₄ (2×25 mL), sat. NaHCO₃ (2×25 mL), water (2×25 mL) and brine (1×25 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet ether) to give a white solid identified as 3-[N^(α)-(tert-butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]thiazolidine (2.55 g, 4.85 mmol, 81%).

B. 3-[N^(α)-(tert-Butyloxycarbonyl)-L-lysinyl]thiazolidine

3-[N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]thiazolidine (1.15 g, 2.13 mmol) was dissolved in acetonitrile (20 mL). Diethylamine (5 mL) was added. After 90 min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 3-[N^(α)-(tert-butyloxycarbonyl)-L-lysinyl]thiazolidine (530 mg, 1.67 mmol, 78%).

C. 3-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω),N^(ω)-(dicinnamyl)-L-lysinyl)thiazolidine

3-(N^(α)-(tert-Butyloxycarbonyl)-L-lysinyl)thiazolidine (200 mg, 0.6 mmol) was dissolved in methanol (25 mL). To this solution was added trans-cinnamaldehyde (400 mg, 3.0 mmol). After 30 mins sodium triacetoxyborohydride (534 mg, 2.54 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 2% methanol, 98% chloroform) to give a colourless oil identified as 3-(N^(α)-(tert-butyloxycarbonyl)-N^(ω),N^(ω)-(dicinnamyl)-L-lysinyl)thiazolidine (139 mg, 0.25 mmol, 40%).

D. 3-[N^(ω),N^(ω)-(Dicinnamyl)-L-lysinyl]thiazolidine dihydrochloride

3-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω), N^(ω)-(di-cinnamyl)-L-lysinyl)thiazolidine (139 mg, 0.25 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pale brown solid identified as 3-[N^(ω),N^(ω)-(dicinnamyl)-L-lysinyl]thiazolidine dihydrochloride (127 mg, 0.24 mmol, 96%).

[M+H]⁺=450.2

¹H NMR (CD₃OD): δ 1.49-1.55 (2H, m), 1.89-1.98 (4H, m), 3.01-3.30 (4H, m), 3.4-3.5 (4H, m), 3.7-3.9 (3H, m), 4.0-4.2 (3H, m), 4.2-4.8 (2H, br m), 6.38-6.44 (2H, m), 6.99-6.93 (2H, m), 7.34-7.37 (5H, m), 7.51-7.60 (4H, m) ppm.

Example 6 3-[N^(ω),N^(ω)-(Cinnamyl)-L-lysinyl]thiazolidine dihydrochloride

A. 3-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω),N^(ω)-(cinnamyl)-L-lysinyl)thiazolidine

3-(N^(α)-(tert-Butyloxycarbonyl)-L-lysinyl)thiazolidine (200 mg, 0.6 mmol) was dissolved in methanol (25 mL). To this solution was added trans-cinnamaldehyde (400 mg, 3.0 mmol). After 30 mins sodium triacetoxyborohydride (534 mg, 2.54 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% triethylamine, 5% methanol, 94% chloroform) to give a colourless oil identified as 3-(N^(α)-(tert-butyloxycarbonyl)-N^(ω), N^(ω)-(cinnamyl)-L-lysinyl)thiazolidine (215 mg, 0.50 mmol, 83%).

B. 3-[N^(ω),N^(ω)-(Cinnamyl)-L-lysinyl]thiazolidine dihydrochloride

3-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω),N^(ω)-(cinnamyl)-L-lysinyl)thiazolidine (215 mg, 0.5 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pale brown solid identified as 3-[N^(ω),N^(ω)-(cinnamyl)-L-lysinyl]thiazolidine dihydrochloride (160 mg, 0.40 mmol, 79%).

[M+H]⁺=334.4

¹H NMR (CD₃OD): δ 1.28-1.30 (1H, m), 1.51-1.53 (1H, m), 1.79-1.78 (1H, m), 1.93-1.98 (2H, m), 2.9-3.3 (5H, m), 3.6-3.8 (5H, m), 4.30-4.70 (5H, m), 6.2-6.3 (1H, m), 6.85-6.91 (1H, m), 7.1-7.7 (5H, m) ppm.

Example 7 1-[N^(ω)-(Cyclohexylmethyl)-L-ornithinyl]pyrrolidine dihydrochloride

A. 1-[N^(ω)-(Benzyloxycarbonyl)-N^(α)-(tert-butyloxycarbonyl)-L-ornithinyl]pyrrolidine

N^(ω)-(Benzyloxycarbonyl)-N^(α)-(tert-butyloxycarbonyl)-L-ornithine (5.49 g, 15 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 100 mL). To this solution at 0° C. was added 1-hydroxybenzotriazole hydrate (3.37 g, 22 mmol), water-soluble carbodiimide (3.46 g, 18 mmol), pyrrolidine (1.28 g, 18 mmol) and N-methylmorpholine (2.0 g, 20 mmol). After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (200 mL). The solution was washed with 0.3M KHSO₄ (2×50 mL), sat. NaHCO₃ (2×50 mL), water (2×50 mL) and brine (1×50 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 90% ethyl acetate, 10% pet. ether) to give a colourless oil identified as 1-[N^(ω)-(benzyloxycarbonyl)-N^(α)-(tert-butyloxycarbonyl)-L-ornithinyl]pyrrolidine (5.15 g, 12.3 mmol, 82%).

B. 1-[N^(α)-(tert-Butyloxycarbonyl)-L-ornithinyl]pyrrolidine

1-[N^(ω)-(Benzyloxycarbonyl)-N^(α)-(tert-butyloxycarbonyl)-L-ornithinyl]pyrrolidine (2.15 g, 5.13 mmol) was dissolved in methanol (80 mL). This solution was hydrogenated over 10% Pd/C (400 mg). After 2 h the catalyst was filtered off and washed with methanol (50 mL). The combined filtrates were evaporated in vacuo to give an off white solid identified as 1-[N^(α)-(tert-butyloxycarbonyl)-L-ornithinyl]pyrrolidine (1.35 g, 4.74 mmol, 94%).

C. 1-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(cyclohexylmethyl)-L-ornithinyl)pyrrolidine

1-[N^(α)-(tert-Butyloxycarbonyl)-L-ornithinyl]pyrrolidine (100 mg, 0.35 mmol) was dissolved in methanol (25 mL). To this solution was added cyclohexanecarboxaldehyde (44 mg, 0.39 mmol). After 30 mins sodium triacetoxyborohydride (148 mg, 0.70 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% triethylamine, 5% methanol, 94% chloroform) to give a colourless oil identified as 1-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(cyclohexylmethyl)-L-ornithinyl)pyrrolidine (51 mg, 0.18 mmol, 52%).

D. 1-[N^(ω)-(Cyclohexylmethyl)-L-ornithinyl]pyrrolidine dihydrochloride

1-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(cyclohexylmethyl)-L-ornithinyl)pyrrolidine (215 mg, 0.5 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[N^(ω)-(cyclohexylmethyl)-L-ornithinyl]pyrrolidine dihydrochloride (160 mg, 0.40 mmol, 79%).

[M+H]⁺=282.3

¹H NMR (CD₃OD): δ 0.93-1.24 (3H, m), 1.66-1.81 (15H, m), 2.50-2.70 (2H, m), 2.71-2.88 (2H, m), 3.2-3.48 (6H, m), 4.08 (1H, m), 8.35-8.38 (1H, m), 8.80-8.85 (1H, m) ppm.

Example 8 3-[N^(ω)-Me-N^(ω)-(2-napthylmethyl)-L-lysinyl]thiazolidine dihydrochloride

A. N^(α)-(tert-Butyloxycarbonyl-N^(ω)-benzyl-L-lysine methyl ester

N^(α)-(tert-Butyloxycarbonyl-L-lysine methyl ester (6.1 g, 22.2 mmol) was dissolved in methanol (100 mL). To this solution was added benzaldehyde (1.9 g, 17.5 mmol). After 2 hours sodium triacetoxyborohydride (5.8 g, 27.3 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (200 mL). This solution was washed with sat Na HCO₃ (1×50 mL), water (12×50 mL) and brine (1×50 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid, 5% methanol, 94% chloroform) to give a colourless oil identified as N^(α)-(tert-butyloxycarbonyl-N^(ω)-benzyl-L-lysine methyl ester (5.2 g, 14.2 mmol, 82%).

B. N^(α)-tert-Butyloxycarbonyl-N^(ω)-benzyl-N^(ω)-methyl-L-lysine methyl ester

N^(α)-tert-Butyloxycarbonyl-N^(ω)-benzyl-L-lysine methyl ester (5.0 g, 14.2 mmol) was dissolved in methanol (100 mL). To this solution was added formaldehyde (37% solution in water, 10 mL). After 2 hours sodium triacetoxyborohydride (3.9 g, 18.4 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (200 mL). This solution was washed with sat. Na HCO₃ (1×50 mL), water (12×50 mL) and brine (1×50 mL), dried (Na₂SO₄) and evaporated in vacuo to give a colourless oil identified as N^(α)-tert-butyloxycarbonyl-N^(ω)-benzyl-N^(ω)-methyl-L-lysine methyl ester (5.2 g, 14.2 mmol, 100%).

C. N^(α)-tert-Butyloxycarbonyl-N^(ω)-methyl-L-lysine methyl ester

N^(α)-tert-Butyloxycarbonyl-N^(ω)-benzyl-N^(ω)-methyl-L-lysine methyl ester (5.0 g, 14.2 mmol) was dissolved in methanol/water (9:1, 100 mL). To this solution was added ammonium formate (1.6, 19.3 mmol) and 10% palladium on charcoal (2 g). After 3 hours at 60° C. the catalyst was filtered off through celite and the residue washed with methanol (50 mL). The combined filtrates were evaporated in vacuo and the residue was taken up in chloroform (200 mL). This solution was washed with sat Na HCO₃ (1×50 mL), water (12×50 mL) and brine (1×50 mL), dried (Na₂SO₄) and evaporated in vacuo to give a colourless oil identified as N^(α)-(tert-butyloxycarbonyl-N^(ω)-methyl-L-lysine methyl ester (3.48 g, 12.5 mmol, 93%).

D. N^(α)-tert-Butyloxycarbonyl-N^(ω)-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-N^(ω)-methyl-L-lysine methyl ester

N^(α)-tert-Butyloxycarbonyl-N^(ω)-methyl-L-lysine methyl ester (3.1 g, 11.1 mmol) was dissolved in dichloromethane (100 mL). To this solution was added 1,1-dimethyl-2,2,2-trichloroethyl chloroformate (3.0 g, 12.5 mmol) and triethylamine (2.3 g, 23 mmol). After 18 hours at room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (200 mL). This solution was washed with 0.3M KHSO₄ (1×50 mL), sat NaHCO₃ (1×50 mL), water (1×50 mL) and brine (1×50 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil purified by flash chromatography on silica gel (eluant: 30% ethyl acetate, 70% pet. ether) to give colourless oil identified as N^(α)-(tert-butyloxycarbonyl-N^(ω)-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-N^(ω)-methyl-L-lysine methyl ester (3.28 g, 6.98 mmol, 63%).

E. N^(α)-tert-Butyloxycarbonyl-N^(ω)-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-N^(ω)-methyl-L-lysine

N^(α)-(tert-Butyloxycarbonyl-N^(ω)-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-N^(ω)-methyl-L-lysine methyl ester (3.1 g, 6.6 mmol) was dissolved in tetrahydrofuran (100 mL). 1M Lithium hydroxide (7 mL, 7.0 mmol) was added. After 3 hours at room temperature the reaction mixture was diluted with ethyl acetate (150 mL), washed with 1M HCl (1×50 mL), water (1×50 mL) and brine (1×50 mL), dried (Na₂SO₄) and evaporated in vacuo to give colourless oil identified as N^(α)-(tert-butyloxycarbonyl-N^(ω)-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-N^(ω)-methyl-L-lysine (2.94 g, 6.45 mmol, 98%).

F. 3-(N^(α)-tert-Butyloxycarbonyl-N^(ω)-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-N^(ω)-methyl-L-lysinyl)thiazolidine

N^(α)-(tert-Butyloxycarbonyl-N^(ω)-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-N^(ω)-methyl-L-lysine (700 mg, 1.51 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 20 mL). To this solution at 0° C. were added 1-hydroxybenzotriazole hydrate (410 mg, 3.0 mmol), water-soluble carbodiimide (250 mg, 1.3 mmol), thiazolidine (170 mg, 1.9 mmol) and N-methylmorpholine (1.0 g, 10 mmol). After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (70 mL). The solution was washed with 0.3M KHSO₄ (1×25 mL), sat. NaHCO₃ (1×25 mL), water (1×25 mL) and brine (1×25 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 50% ethyl acetate, 50% pet. ether) to give a white solid identified as 3-(N^(α)-tert-butyloxycarbonyl-N^(ω)-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-N^(ω)-methyl-L-lysinyl)thiazolidine (758 mg, 1.42 mmol, 94%).

G. 3-(N^(α)-tert-Butyloxycarbonyl-N^(ω)-methyl-L-lysinyl)thiazolidine

3-(N^(α)-tert-Butyloxycarbonyl-N^(ω)-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-N^(ω)-methyl-L-lysinyl)thiazolidine (730 mg, 1.36 mmol) was dissolved in acetic acid (30 mL). Zinc powder (200 mg) was added. After stirring at room temperature for 18 hours the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). The solution was washed with sat. NaHCO₃ (1×25 mL), water (1×25 mL) and brine (1×25 mL), dried (Na₂SO₄) and evaporated in vacuo to give a colourless oil identified as 3-(N^(α)-tert-butyloxycarbonyl-N^(ω)-methyl-L-lysinyl)thiazolidine (438 mg, 1.32 mmol, 97%).

H. 3-[N^(α)-tert-Butyloxycarbonyl-N^(ω)-methyl-N^(ω)-(2-napthylmethyl)-L-lysinyl]thiazolidine

3-(N^(α)-tert-Butyloxycarbonyl-N^(ω)-methyl-L-lysinyl)thiazolidine (50 mg, 0.15 mmol) was dissolved in 1,2-dichloroethane (20 mL). To this solution was added 2-naphtaldehyde (26 mg, 0.17 mmol). After 2 hours sodium triacetoxyborohydride (36 mg, 0.17 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 4% methanol, 96% chloroform) to give a colourless oil identified as 3-[N^(α)-tert-butyloxycarbonyl-N^(ω)-methyl-N^(ω)-(2-napthylmethyl)-L-lysinyl]thiazolidine (51 mg, 0.11 mmol, 72%).

I. 3-[N^(ω)-Methyl-N^(ω)-(2-napthylmethyl)-L-lysinyl]thiazolidine dihydrochloride

3-[N^(α)-tert-Butyloxycarbonyl-N^(ω)-methyl-N^(ω)-(2-napthylmethyl)-L-lysinyl]thiazolidine (44 mg, 0.093 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pale brown solid identified as 3-[N^(ω)-methyl-N^(ω)-(2-napthylmethyl)-L-lysinyl]thiazolidine dihydrochloride (37 mg, 0.083 mmol, 89%).

[M+H]⁺=372.2

¹H NMR (CD₃OD): δ 1.50-1.53 (2H, m), 1.91-1.98 (4H, m), 2.82 (3H, s), 3.08-3.19 (4H, m), 3.36-3.75 (5H, m), 4.32-4.47 (2H, m), 4.60-4.71 (2H, m), 7.55-7.59 (2H, m), 7.65-7.68 (1H, m), 7.90-8.00 (3H, m), 8.10-8.12 (1H, m) ppm.

Example 9 3-[N^(ω)-Methyl-N^(ω)-(1-Napthylmethyl)-L-ornithyl]thiazolidine dihydrochloride

A. 3-[N-(tert-Butyloxycarbonyl)-O^(ω)-methyl-L-glutamyl]thiazolidine

N-(tert-Butyloxycarbonyl)-O^(ω)-methyl-L-glutamic acid (6.28 g, 24 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 100 ml). To this solution at 0° C. were added 1-hydroxybenzotriazole hydrate (5.5 g, 36 mmol), water-soluble carbodiimide (5.38 g, 28 mmol), thiazolidine (2.48 g, 28 mmol) and N-methylmorpholine (3.0 g, 30 mmol). The mixture was stirred for 18 h at 0° C. to room temperature then the solvent was removed in vacuo and the residue was taken up in ethyl acetate (150 ml). The solution was washed with 0.3M KHSO₄ (2×30 ml), sat. NaHCO₃ (2×30 ml), water (2×30 ml) and brine (1×30 ml), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 70% ethyl acetate, 30% pet. ether 60-80) to give a brown oil identified as 3-[N-(tert-butyloxycarbonyl)-O^(ω)-methyl-L-glutamyl]thiazolidine (4.0 g, 12 mmol, 50%).

B. 3-[N,N-Di-(tert-butyloxycarbonyl)-O^(ω)-methyl-L-glutamyl]thiazolidine

3-[N-(tert-Butyloxycarbonyl)-O^(ω)-methyl-L-glutamyl]thiazolidine (3.2 g, 9.6 mmol) was dissolved in acetonitrile (20 mL). Di-tert-butyl dicarbonate (3.14 g, 14.4 mmol) and 4-dimethylaminopyridine (235 mg, 1.93 mmol) were added. After 18 hours at room temperature further di-tert-butyl dicarbonate (3.14 g, 14.4 mmol) was added. After a further 3 days at room temperature the solvent was evaporated in vacuo the residue was purified by flash chromatography on silica gel (eluant: 70% ethyl acetate, 30% pet. ether 60-80) to give a colourless oil identified as 3-[N,N-di-(tert-butyloxycarbonyl)-O^(ω)-methyl-L-glutamyl]thiazolidine (2.0 g, 4.63 mmol, 48%).

C. 3-[N,N-Di-(tert-butyloxycarbonyl)-L-glutamyl]thiazolidine

3-[N,N-di-(tert-butyloxycarbonyl)-O^(ω)-methyl-L-glutamyl]thiazolidine (950 mg, 2.22 mmol) was dissolved in THF (50 ml). 1M Lithium hydroxide (5.5 ml, 5.5 mmol) was added. The mixture was stirred for 1 hour at room temperature then the solvent was removed in vacuo and the residue was taken up in ethyl acetate (70 ml). The solution was washed with 0.3M KHSO₄ (2×20 ml), water (2×20 ml) and brine (1×20 ml), dried (Na₂SO₄) and evaporated in vacuo to give a colourless oil identified as 3-[N,N-di-(tert-butyloxycarbonyl)-L-glutamyl]thiazolidine (912 mg, 2.2 mmol, 98%).

D. 3-[2-(N,N-Di-(tert-butyloxycarbonyl)amino)-5-hydroxypentanoyl]thiazolidine

3-[N,N-Di-(tert-butyloxycarbonyl)-L-glutamyl]thiazolidine (912 mg, 2.2 mmol) was dissolved in tetrahydrofuran (30 mL). This solution was cooled to −20° C., N-methylmorpholine (300 mg, 2.96 mmol) and isobutyl chloroformate (387 mg, 2.83 mmol) were added. After 20 mins at −20° C. the reaction mixture was added to a solution of sodium borohydride (182 mg, 4.8 mmol) in water (5 mL) at 0° C. After 1 hour the reaction mixture was diluted with ethyl acetate (150 mL). This solution was washed with water (1×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a colourless oil identified as 3-[2-(N,N-di-(tert-butyloxycarbonyl)amino)-5-hydroxy-pentanoyl]thiazolidine (800 mg, 2.0 mmol, 92%).

E. 3-[2-(N,N-Di-(tert-butyloxycarbonyl)amino-5-oxopentanoyl]thiazolidine

3-[2-N,N-((Di-tert-butyloxycarbonyl)amino)-5-hydroxypentanoyl]thiazolidine (800 mg, 2.0 mmol) was dissolved in dichloromethane (50 mL). Dess-Martin periodinane (933 mg, 2.2 mmol) was added. After 1 hour at room temperature the reaction mixture was diluted with ethyl acetate (150 mL). This solution was washed with water (1×20 ml) and brine (1×20 ml), dried (Na₂SO₄) and evaporated in vacuo to give a colourless oil. Purified by flash chromatography on silica gel (eluant: 50% ethyl acetate, 50% pet. ether 60-80) to give a colourless oil identified as 3-[2-(N,N-di-(tert-butyloxycarbonyl)amino-5-oxopentanoyl]thiazolidine (210 mg, 0.52 mmol, 26%).

F. 3-[N,N-Di-(tert-butyloxycarbonyl-N^(ω)-methyl-N^(ω)-(1-napthylmethyl)-L-ornithyl]-thiazolidine

3-[N,N-Di-(tert-butyloxycarbonyl)amino-5-oxopentanoyl]thiazolidine was dissolved in 1,2-dichloroethane (20 mL). To this solution was added N-methyl-1-napthylmethylamine. After 2 hours sodium triacetoxyborohydride was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel to give a colourless oil identified as 3-[N,N-di-(tert-butyloxycarbonyl-N^(ω)-methyl-N^(ω)-(1-napthylmethyl)-L-ornithyl]thiazolidine.

G. 3-[N^(ω)-Methyl-N^(ω)-(1-Napthylmethyl)-L-ornithyl]thiazolidine dihydrochloride

3-[N,N-Di-(tert-butyloxycarbonyl-N^(ω)-methyl-N^(ω)-(1-napthylmethyl)-L-ornithyl]thiazolidine was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pale brown solid identified as 3-[N^(ω)-Me,N^(ω)-(1-napthylmethyl)-L-ornithyl]thiazolidine dihydrochloride.

Example 10 3,3-Difluoro-1-[N^(ω)-(2-methylbutyl)-L-lysinyl]pyrrolidine dihydrochloride

A. 1-(tert-Butyloxycarbonyl)-3-pyrrolidone

(3R)-1-(tert-Butyloxycarbonyl)-3-hydroxypyrrolidine (980 mg, 5.3 mmol) was dissolved in CH₂Cl₂ (40 ml). Dess-Martin periodinane (2.5 g, 5.8 mmol) was added. The mixture was stirred for 3 hours at room temperature then the solvent was removed in vacuo and the residue was taken up in ethyl acetate (300 ml). The solution was washed with sat. NaHCO₃, water and brine, dried (Na₂SO₄) and evaporated in vacuo to give a colourless oil. The residue was purified by flash chromatography on silica gel (eluant: 20% ethyl acetate, 80% pet. ether 60-80) to give a colourless oil identified as 1-(tert-butyloxycarbonyl)-3-pyrrolidone (842 mg, 4.6 mmol, 87%).

B. 1-(tert-Butyloxycarbonyl)-3,3-difluoropyrrolidine

1-(tert-Butyloxycarbonyl)-3-pyrrolidone (810 mg, 4.4 mmol) was dissolved in CH₂Cl₂ (30 ml). (Diethylamino)sulphur trifluoride (2.2 g, 13.7 mmol) was added to this solution at 0° C. The mixture was stirred for 18 hours at 0° C. to room temperature then carefully poured into sat. NaHCO₃ (100 ml). The mixture was stirred for 15 min then extracted with CH₂Cl₂. The organic extract was washed with water and brine, dried (Na₂SO₄) and evaporated in vacuo to give an orange oil. The residue was purified by flash chromatography (eluant: 10% ethyl acetate, 90% pet. ether 60-80) to give a colourless oil identified as 1-(tert-butyloxycarbonyl)-3,3-difluoropyrrolidine (580 mg, 2.8 mmol, 64%).

C. 3,3-Difluoropyrrolidine hydrochloride

1-(tert-Butyloxycarbonyl)-3,3-difluoropyrrolidine (540 mg, 2.6 mmol) was dissolved in 4M HCl/dioxan (30 ml). The solution was stirred for 1 hour at room temperature then the solvent was removed in vacuo to give an off white solid identified as 3,3-difluoropyrrolidine hydrochloride (370 mg, 2.6 mmol, 100%).

D. 1-[N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]-3,3-difluoropyrrolidine

N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysine (1.14 g, 2.4 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 100 ml). To this solution at 0° C. were added 1-hydroxybenzotriazole hydrate (394 mg, 2.9 mmol), water-soluble carbodiimide (680 mg, 3.4 mmol), 3,3-difluoropyrrolidine hydrochloride (380 mg, 2.43 mmol) and N-methylmorpholine (400 mg, 4 mmol). The mixture was stirred for 18 h at 0° C. to room temperature then the solvent was removed in vacuo and the residue was taken up in ethyl acetate (200 ml). The solution was washed with 0.3M KHSO₄, sat. NaHCO₃, water and brine, dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 65% ethyl acetate, 35% pet. ether 60-80) to give a white solid identified as 1-[N^(α)-(tert-butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]-3,3-difluoropyrrolidine (1.0 g, 1.8 mmol, 75%).

E. 1-[N^(α)-(tert-Butyloxycarbonyl)-L-lysinyl]-3,3-difluoropyrrolidine

1-[N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]-3,3-difluoro-pyrrolidine (1.01 g, 1.8 mmol) was dissolved in THF (20 ml). Diethylamine (5 ml) was added. The mixture was stirred for 3 hours at room temperature then the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 1-[N^(α)-(tert-butyloxycarbonyl)-L-lysinyl]-3,3-difluoropyrrolidine (598 mg, 1.78 mmol, 99%).

F. 1-[N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(2-methylbutyl)-L-lysinyl]-3,3-difluoro-pyrrolidine

1-[N^(α)-(tert-Butyloxycarbonyl)-L-lysinyl]-3,3-difluoropyrrolidine was dissolved in 1,2-dichloroethane (20 mL). To this solution was added 2-methylbutanal. After 2 hours sodium triacetoxyborohydride was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel to give a colourless oil identified as 1-[N^(α)-(tert-butyloxycarbonyl)-N^(ω)-(2-methylbutyl)-L-lysinyl]-3,3-difluoropyrrolidine.

G. 3,3-Difluoro-1-[N^(ω)-(2-methylbutyl)-L-lysinyl]pyrrolidine dihydrochloride

1-[N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(2-methylbutyl)-L-lysinyl]-3,3-difluoropyrrolidine was dissolved in 4M HCl/dioxan (20 ml). The mixture was stirred for 1 hour at room temperature then the solvent was removed in vacuo to give a colourless oil identified as 3,3-difluoro-1-[N^(ω)-(2-methylbutyl)-L-lysinyl]pyrrolidine dihydrochloride.

Example 11 1-[N^(ω)-(3-Cyclohexenylmethyl)-L-lysinyl]thiomorpholine dihydrochloride

A. 3-[N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]thiomorpholine

N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysine (2.5 g, 5.34 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 100 mL). To this solution at 0° C. were added 1-hydroxybenzotriazole hydrate (1.44 g, 10.6 mmol), water-soluble carbodiimide (1.35 g, 6.5 mmol), thiomorpholine (710 mg, 6.9 mmol) and N-methylmorpholine (800 mg, 8 mmol). After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100 mL). The solution was washed with 0.3M KHSO₄ (2×25 mL), sat. NaHCO₃ (2×25 mL), water (2×25 mL) and brine (1×25 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a white solid identified as 3-[N^(α)-(tert-butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]thiomorpholine (2.70 g, 4.88 mmol, 91%).

B. 3-[N^(α)-(tert-Butyloxycarbonyl)-L-lysinyl]thiomorpholine

3-[N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(9-fluorenylmethyloxycarbonyl)-L-lysinyl]thiomorpholine (2.6 g, 4.7 mmol) was dissolved in tetrahydrofuran (20 mL). Diethylamine (5 mL) was added. After 90 min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 3-[N^(α)-(tert-butyloxycarbonyl)-L-lysinyl]thiomorpholine (1.2 g, 3.637 mmol, 77%).

C. 3-[N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(3-cyclohexenylmethyl)-L-lysinyl]-thiomorpholine

3-(N^(α)-(tert-Butyloxycarbonyl)-L-lysinyl)thiomorpholine (150 mg, 0.45 mmol) was dissolved in methanol (25 mL). To this solution was added 3-cyclohexanecarboxaldehyde (400 mg, 0.45 mmol). After 30 mins sodium triacetoxyborohydride (150 mg, 0.71 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid, 9% methanol, 90% chloroform) to give a colourless oil identified as 3-(N^(α)-(tert-butyloxycarbonyl)-N^(ω)-(3-cyclohexenylmethyl)-L-lysinyl)thiomorpholine (66 mg, 0.12 mmol, 26%).

D. 1-[N^(ω)-(3-Cyclohexenylmethyl)-L-lysinyl]thiomorpholine dihydrochloride

3-(N^(α)-(tert-Butyloxycarbonyl)-N^(ω)-(3-cyclohexenylmethyl)-L-lysinyl)thiomorpholine (66 mg, 0.12 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[N^(ω)-(3-cyclohexenylmethyl)-L-lysinyl]thiomorpholine dihydrochloride (62 mg, 0.12 mmol, 100%).

[M+H]⁺=326.2

Example 12 (2S)-1-[N^(ω)-(2-(3′-trifluoromethylanilino)pyridyl-3-carbonyl)-L-ornithyl]thiazolidine dihydrochloride

A. 3-[N^(α)-tert-Butyloxycarbonyl-N^(ω)-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-L-ornithyl]thiazolidine

N^(α)-(tert-Butyloxycarbonyl-N^(ω)-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-L-ornithine (2.5 g, 5.9 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 30 mL). To this solution at 0° C. were added 1-hydroxybenzotriazole hydrate (1.6 g, 11.9 mmol), water-soluble carbodiimide (1.4 g, 7.6 mmol), thiazolidine (650 mg, 7.3 mmol) and N-methylmorpholine (2.0 g, 20 mmol). After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (70 mL). The solution was washed with 0.3M KHSO₄ (1×25 mL), sat. NaHCO₃ (1×25 mL), water (1×25 mL) and brine (1×25 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 70% ethyl acetate, 30% pet. ether) to give a colourless oil identified as 3-[N^(α)-tert-butyloxycarbonyl-N^(ω)-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-L-ornithyl]thiazolidine (758 mg, 1.42 mmol, 94%).

B. 3-(N^(α)-tert-Butyloxycarbonyl-L-ornithinyl)thiazolidine

3-[N^(α)-tert-Butyloxycarbonyl-N^(ω)-(1,1-dimethyl-2,2,2-trichloroethoxycarbonyl)-L-ornithyl]thiazolidine (130 mg, 0.26 mmol) was dissolved in acetic acid (30 mL). Zinc powder (100 mg) was added. After stirring at room temperature for 18 hours the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). The solution was washed with sat. NaHCO₃ (1×25 mL), water (1×25 mL) and brine (1×25 mL), dried (Na₂SO₄) and evaporated in vacuo to give a colourless oil identified as 3-(N^(α)-tert-butyloxycarbonyl-L-ornithinyl)thiazolidine (80 mg, 0.26 mmol, 100%).

C. 3-[N^(α)-tert-Butyloxycarbonyl-N^(ω)-(2-(3′-trifluoromethylanilino)pyridyl-3-carbonyl)-L-ornithinyl]thiazolidine

3-(N^(α)-tert-Butyloxycarbonyl-L-ornithinyl)thiazolidine (80 mg, 0.26 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 20 mL). To this solution at 0° C. was added 1-hydroxybenzotriazole hydrate (80 mg, 0.6 mmol), water-soluble carbodiimide (65 mg, 0.32 mmol), niflumic acid (82 mg, 0.29 mmol) and N-methylmorpholine (100 mg, 1.0 mmol). After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (70 mL). The solution was washed with 0.3M KHSO₄ (1×20 mL), sat. NaHCO₃ (1×20 mL), water (1×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a yellow oil identified as 3-[N^(α)-tert-butyloxycarbonyl-N^(ω)-(2-(3′-trifluoromethylanilino)pyridyl-3-carbonyl)-L-ornithinyl]-thiazolidine (60 mg, 0.12 mmol, 45%).

D. (2S)-1-[N^(ω)-(2-(3′-Trifluoromethylanilino)pyridyl-3-carbonyl)-L-ornithyl]-thiazolidine dihydrochloride

3-[N^(α)-tert-Butyloxycarbonyl-N^(ω)-(2-(3′-trifluoromethylanilino)pyridyl-3-carbonyl)-L-ornithinyl]thiazolidine (54 mg, 0.10 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pale brown solid identified as (2S)-1-[N^(ω)-(2-(3′-trifluoromethylanilino)pyridyl-3-carbonyl)-L-ornithyl]thiazolidine dihydrochloride (47 mg, 0.10 mmol, 100%).

[M+H]⁺=468.0

¹H NMR (CD₃OD): δ 1.77-1.82 (2H, m), 1.84-2.00 (2H, m), 3.03-3.15 (4H, m), 3.41-3.51 (2H, m), 3.65-3.71 (2H, m), 3.80-3.87 (1H, m), 4.46-4.49 (2H, m), 4.65-4.72 (2H, m), 7.06-7.11 (1H, m), 7.61-7.11 (3H, m), 7.95 (1H, s), 8.09 (1H, d, J=4.7 Hz), 8.49 (1H, d, J=4.2 Hz) ppm.

Example 13 3,3-Difluoro-1-[N^(ω)-(2-(3′-chloroanilino)pyridyl-3-carbonyl)-L-ornithyl]pyrrolidine dihydrochloride

A. 1-[N^(α)-(tert-Butyloxycarbonyl)-L-ornithyl]-3,3-difluoropyrrolidine

1-[N^(α)-(tert-Butyloxycarbonyl)-L-ornithyl]-3,3-difluoropyrrolidine was prepared as described for the lysine derivative in Example 9.

B. 3-Chloroanilinonicotinic acid

3-Chloroaniline was dissolved in xylene. 2-Aminonicotinic acid was added. The reaction mixture was heated at 150° C. for 18 hours after which time the reaction mixture was diluted with ethyl acetate giving an off-white solid identified as 3-chloroanilinonicotinic acid.

C. 3,3-Difluoro-[N^(α)-tert-butyloxycarbonyl-N^(ω)-(2-(3′-chloroanilino)pyridyl-3-carbonyl)-L-ornithinyl]pyrrolidine

1-[N^(α)-(tert-Butyloxycarbonyl)-L-ornithyl]-3,3-difluoropyrrolidine was dissolved in CH₂Cl₂/DMF (9:1, 20 mL). To this solution at 0° C. was added 1-hydroxybenzotriazole hydrate, water-soluble carbodiimide, 3-chloroanilinonicotinic acid and N-methylmorpholine. After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (70 mL). The solution was washed with 0.3M KHSO₄ (1×20 mL), sat. NaHCO₃ (1×20 mL), water (1×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a yellow oil identified as 3,3-difluoro-[N^(α)-tert-butyloxycarbonyl-N^(ω)-(2-(3′-chloroanilino)pyridyl-3-carbonyl)]-L-ornithinyl)pyrrolidine.

D. 3,3-Difluoro-1-[N^(ω)-(2-(3′-chloroanilino)pyridyl-3-carbonyl)-L-ornithyl]pyrrolidine dihydrochloride

3,3-Difluoro-[N^(α)-tert-butyloxycarbonyl-N^(ω)-(2-(3′-chloroanilino)pyridyl-3-carbonyl)]-L-ornithinyl)pyrrolidine was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pale brown solid identified as 3,3-difluoro-1-[N^(ω)-(2-(3′-chloroanilino)pyridyl-3-carbonyl)-L-ornithyl]pyrrolidine dihydrochloride.

Example 14 3-[N^(ω)-6-Chloro-4-(2′,5′-dichloroanilino)-1,3,5-triazinyl)-L-lysinyl]thiazolidine dihydrochloride

A. 4,6-Dichloro-2-(2′,5′-dichloroanilino)-1,3,5-triazine

Cyanuric chloride (1.844 g, 10 mmol) was dissolved in acetonitrile (20 mL). The solution was cooled to −20° C. A solution of 2,5-dichloroaniline (1.62 g, 10 mmol) and triethylamine (1.0 g, 10 mmol) was slowly added. After 1 hour at −20° C. the solvent was removed in vacuo and the residue was taken up in ethyl acetate (150 mL). The solution was washed with water (1×50 mL) and brine (1×50 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was recrystallised from ethyl acetate/hexane to give an off white solid identified as 4,6-dichloro-2-(2′,5′-dichloroanilino)-1,3,5-triazine (1.86 mg, 6.0 mmol, 60%).

B. 3-[N^(α)-tert-Butyloxycarbonyl-N^(ω)-6-chloro-4-(2′,5′-dichloroanilino)-1,3,5-triazinyl)-L-lysinyl]thiazolidine

3-(N^(α)-(tert-Butyloxycarbonyl)-L-lysinyl)thiazolidine (800 mg, 2.58 mmol) was dissolved in dichloromethane (30 mL). To this solution was added 4,6-dichloro-2-(2′,5′-dichloroanilino)-1,3,5-triazine (810 mg, 2.6 mmol) and triethylamine (300 mg, 3.0 mmol). After 2 hours at room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (150 mL). This solution was washed with water (2×30 mL) and brine (1×30 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography (eluant: 60% ethyl acetate, 40% pet. ether) to give a white solid identified as 3-[N^(α)-tert-butyloxycarbonyl-N^(ω)-6-chloro-4-(2′,5′-dichloroanilino)-1,3,5-triazinyl)-L-lysinyl]thiazolidine (1.33 g, 2.23 mmol, 86%).

C. 3-[N^(ω)-6-Chloro-4-(2′,5′-dichloroanilino)-1,3,5-triazinyl)-L-lysinyl]thiazolidine dihydrochloride

3-[N^(α)-tert-Butyloxycarbonyl-N^(ω)-6-chloro-4-(2′,5′-dichloroanilino)-1,3,5-triazinyl)-L-lysinyl]thiazolidine (59 mg, 0.10 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 3-[N^(ω)-6-chloro-4-(2′,5′-dichloroanilino)-1,3,5-triazinyl)-L-lysinyl]thiazolidine dihydrochloride (55 mg, 0.098 mmol, 98%).

[M+H]⁺=492.2, 494.4

¹H NMR (CD₃OD): δ 1.46-1.51 (2H, m), 1.65-1.67 (2H, m), 1.80-1.96 (2H, m), 3.05-3.14 (2H, m), 3.38-3.42 (2H, m), 3.55-3.75 (4H, m), 4.31-4.36 (2H, m0, 4.40-4.52 (1H, m), 4.63-4.95 (2H, m), 7.15-7.18 (1H, m), 7.40-7.45 (1H, m), 8.15-8.25 (1H, m) ppm.

Example 15 3-[N^(ω)-4-(2′,5′-Dichloroanilino)-6-hydroxy-1,3,5-triazinyl)-L-lysinyl]thiazolidine bis(trifluoroacetate)

A. 3-[N^(ω)-4-(2′,5′-Dichloroanilino)-6-hydroxy-1,3,5-triazinyl)-L-lysinyl]thiazolidine bis(trifluoroacetate)

3-[N^(α)-tert-Butyloxycarbonyl-N^(ω)-6-chloro-4-(2′,5′-dichloroanilino)-1,3,5-triazinyl)]-L-ornithinyl)thiazolidine (54 mg, 0.09 mmol) was dissolved in trifluoroacetic acid (20 mL) and water (2 mL). After 2 hours at 70° C. the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 3-[N^(ω)-4-(2′,5′-dichloroanilino)-6-hydroxy-1,3,5-triazinyl)-L-lysinyl]thiazolidine bis(trifluoroacetate) (63 mg, 0.089 mmol, 97%).

[M+H]⁺=472.1, 474.2

¹H NMR (CD₃OD): δ 1.42-1.47 (2H, m), 1.62-1.67 (2H, m), 1.82-1.89 (2H, m), 3.04-3.16 (4H, m), 3.70-3.75 (2H, m), 3.84-3.91 (1H, m), 4.25-4.32 (2H, m), 4.45-4.54 (2H, m), 4.64-4.70 (2H, m), 7.05-7.15 (1H, m), 7.34-7.38 (1H, m), 7.49-7.55 (1H, m), 7.80-7.92 (1H, m) ppm.

Example 16 3-[N^(ω)-4-(2′,5′-Dichloroanilino)-6-methylamino-1,3,5-triazinyl)-L-lysinyl]thiazolidine dihydrochloride

A. 3-[N^(α)-tert-Butyloxycarbonyl-N^(ω)-(2′,5′-dichloroanilino)-6-dimethylamino-1,3,5-triazinyl)-L-lysinyl]thiazolidine

3-[N^(α)-tert-Butyloxycarbonyl-N^(ω)-3-chloro-5-(2′,5′-dichloroanilino)-2,4,6-triazinyl)]-L-ornithinyl)thiazolidine (120 mg, 0.20 mmol) was dissolved in 1M dimethylamine in tetrahydrofuran (25 mL). After 18 hours at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 70% ethyl acetate, 30% pet. ether) to give a white solid identified as 3-[N^(α)-tert-butyloxycarbonyl-N^(ω)-4-(2′,5′-dichloroanilino)-6-dimethylamino-1,3,5-triazinyl)-L-lysinyl]thiazolidine (110 mg, 0.18 mmol, 90%).

B. 3-[N^(ω)-4-(2′,5′-Dichloroanilino)-6-dimethylamino-1,3,5-triazinyl)-L-lysinyl]-thiazolidine dihydrochloride

3-[N^(α)-tert-Butyloxycarbonyl-N^(ω)-4-(2′,5′-dichloroanilino)-6-dimethylamino-1,3,5-triazinyl)-L-lysinyl]thiazolidine (110 mg, 0.18 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 3-[N^(ω)-4-(2′,5′-dichloroanilino)-6-dimethylamino-1,3,5-triazinyl)-L-lysinyl]thiazolidine dihydrochloride (105 mg, 0.18 mmol, 100%).

[M+H]⁺=499.1, 501.1

¹H NMR (CD₃OD): δ 1.52-1.55 (2H, m), 1.69-1.71 (2H, m), 1.90-1.98 (2H, m), 3.13-3.22 (8H, m), 3.48-3.62 (2H, m), 3.65-3.69 (4H, m), 4.37-4.39 (2H, m), 4.46-4.49 (1H, m), 4.57-4.77 (2H, m), 7.20-7.22 (1H, m), 7.45-7.50 (1H, m), 8.09-8.12 (1H, m) ppm.

The following compounds were prepared by analogous methods.

TABLE 1

Example No n X 17 3

1819 34

2021 34

2223 34

2425 34

2627 34

TABLE 2

Example No n X 28 2

293031 234

323334 234

353637 234

383940 234

41 2

424345 234

464748 234

49 2

505152 234

TABLE 3

Ex No a b X R³ R⁴  53 54 55 111 343 S CH₂ HHH

 56 1 4 H  57 1 3 CF₂ H  58 1 4 H  59 1 4 S CH₃  60 1 4 CH(CH₃)₂  61 1 4 CH₂ CH₃  62 1 4 CH(CH₃)₂  63 1 3 S CH(CH₃)₂  64 1 3 CH₂ CH(CH₃)₂  65 2 3 S H  66 2 4 H  67 2 3 CH₂ H  68 2 4 H  69 70 71 72 73 74 75 76 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

 77 1 4 CH₂ CH₃  78 1 4 CH(CH₃)₂  79 1 3 S CH(CH₃)₂  80 1 3 CH₂ CH(CH₃)₂  81 2 3 S H  82 2 4 H  83 2 3 CH₂ H  84 2 4 H  85 86 87 111 343 S CH₂ HHH

 88 1 4 H  89 1 3 CF₂ H  90 1 4 H  91 1 4 S CH₃  92 1 4 CH(CH₃)₂  93 1 4 CH₂ CH₃  94 1 4 CH(CH₃)₂  95 1 3 S CH(CH₃)₂  96 1 3 CH₂ CH(CH₃)₂  97 2 3 S H  98 2 4 H  99 2 3 CH₂ H 100 2 4 H 101102103104105106107108 11111111 34343444 S CH₂ CF₂S CH₂ HHHHHCH₃CH(CH₃)₂CH₃

109 1 4 CH(CH₃)₂ 110 1 3 S CH(CH₃)₂ 111 1 3 CH₂ CH(CH₃)₂ 112 2 3 S H 113 2 4 H 114 2 3 CH₂ H 115 2 4 H 116117118119 1111 3434 S CH₂ HHHH

120 1 3 CF₂ H 121 1 4 H 122 1 4 S CH₃ 123 1 4 CH(CH₃)₂ 124 1 4 CH₂ CH₃ 125 1 4 CH(CH₃)₂ 126 1 3 S CH(CH₃)₂ 127 1 3 CH₂ CH(CH₃)₂ 128 2 3 S H 129 2 4 H 130 2 3 CH₂ H 131 2 4 H 132133134135136137138139 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

140 1 4 CH₂ CH₃ 141 1 4 CH(CH₃)₂ 142 1 3 S CH(CH₃)₂ 143 1 3 CH₂ CH(CH₃)₂ 144 2 3 S H 145 2 4 H 146 2 3 CH₂ H 147 2 4 H 148149150151 1111 3443 S CH₂CF₂

152 1 4 153 1 4 S CH₃ 154 1 4 CH(CH₃)₂ 155 1 4 CH₂ CH₃ 156 1 4 CH(CH₃)₂ 157 1 3 S CH(CH₃)₂ 158 1 3 CH₂ CH(CH₃)₂ 159 2 3 S H 160 2 4 H 161 2 3 CH₂ H 162 2 4 H 163164165166167168169170 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

171 1 4 CH₂ CH₃ 172 1 4 CH(CH₃)₂ 173 1 3 S CH(CH₃)₂ 174 1 3 CH₂ CH(CH₃)₂ 175 2 3 S H 176 2 4 H 177 2 3 CH₂ H 178 2 4 H 179180181182183 11111 34343 S CH₂ CF₂ HHHHH

184 1 4 H 185 1 4 S CH₃ 186 1 4 CH(CH₃)₂ 187 1 4 CH₂ CH₃ 188 1 4 CH(CH₃)₂ 189 1 3 S CH(CH₃)₂ 190 1 3 CH₂ CH(CH₃)₂ 191 2 3 S H 192 2 4 H 193 2 3 CH₂ H 194 2 4 H 195196197198199200201202 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

203 1 4 CH₂ CH₃ 204 1 4 CH(CH₃)₂ 205 1 3 S CH(CH₃)₂ 206 1 3 CH₂ CH(CH₃)₂ 207 2 3 S H 208 2 4 H 209 2 3 CH₂ H 210 2 4 H 211212213214215 11111 34343 S CH₂ CF₂ HHHHH

216 1 4 H 217 1 4 S CH₃ 218 1 4 CH(CH₃)₂ 219 1 4 CH₂ CH₃ 220 1 4 CH(CH₃)₂ 221 1 3 S CH(CH₃)₂ 222 1 3 CH₂ CH(CH₃)₂ 223 2 3 S H 224 2 3 CH₂ H 225 2 4 H 226227228229230231232233 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

234 1 4 CH₂ CH₃ 235 1 4 CH(CH₃)₂ 236 1 3 S CH(CH₃)₂ 237 1 3 CH₂ CH(CH₃)₂ 238 2 3 S H 239 2 4 H 240 2 3 CH₂ H 241 2 4 H 242243244245246247 111111 343434 S CH₂ CF₂ HHHHHH

248 1 4 S CH₃ 249 1 4 CH(CH₃)₂ 250 1 4 CH₂ CH₃ 251 1 4 CH(CH₃)₂ 252 1 3 S CH(CH₃)₂ 253 1 3 CH₂ CH(CH₃)₂ 254 2 3 S H 255 2 4 H 256 2 3 CH₂ H 257 2 4 H 258259260261262263264265 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

266 1 4 CH₂ CH₃ 267 1 4 CH(CH₃)₂ 268 1 3 S CH(CH₃)₂ 269 1 3 CH₂ CH(CH₃)₂ 270 2 3 S H 271 2 4 H 272 2 3 CH₂ H 273 2 4 H 274275276277278279 111111 343434 S CH₂ CF₂ HHHHHH

280 1 4 S CH₃ 281 1 4 CH(CH₃)₂ 282 1 4 CH₂ CH₃ 283 1 4 CH(CH₃)₂ 284 1 3 S CH(CH₃)₂ 285 1 3 CH₂ CH(CH₃)₂ 286 2 3 S H 287 2 4 H 288 2 3 CH₂ H 289 2 4 H 290291292293294295296297 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

298 1 4 CH₂ CH₃ 299 1 4 CH(CH₃)₂ 300 1 3 S CH(CH₃)₂ 301 1 3 CH₂ CH(CH₃)₂ 302 2 3 S H 303 2 4 H 304 2 3 CH₂ H 305 2 4 H 306307308309310311 111111 343434 S CH₂ CF₂ HHHHHH

312 1 4 S CH₃ 313 1 4 CH(CH₃)₂ 314 1 4 CH₂ CH₃ 315 1 4 CH(CH₃)₂ 316 1 3 S CH(CH₃)₂ 317 1 3 CH₂ CH(CH₃)₂ 318 2 3 S H 319 2 4 H 320 2 3 CH₂ H 321 2 4 H 322323324325326327328329 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

330 1 4 CH₂ CH₃ 331 1 4 CH(CH₃)₂ 332 1 3 S CH(CH₃)₂ 333 1 3 CH₂ CH(CH₃)₂ 334 2 3 S H 335 2 4 H 336 2 3 CH₂ H 337 2 4 H 338339340341342343 111111 343434 S CH₂ CF₂ HHHHHH

344 1 4 S CH₃ 345 1 4 CH(CH₃)₂ 346 1 4 CH₂ CH₃ 347 1 4 CH(CH₃)₂ 348 1 3 S CH(CH₃)₂ 349 1 3 CH₂ CH(CH₃)₂ 350 2 3 S H 351 2 4 H 352 2 3 CH₂ H 353 2 4 H 354355356357358359360361 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

362 1 4 CH₂ CH₃ 363 1 4 CH(CH₃)₂ 364 1 3 S CH(CH₃)₂ 365 1 3 CH₂ CH(CH₃)₂ 366 2 3 S H 367 2 4 H 368 2 3 CH₂ H 369 2 4 H 370371372373374375 111111 343434 S CH₂ CF₂ HHHHHH

376 1 4 S CH₃ 377 1 4 CH(CH₃)₂ 378 1 4 CH₂ CH₃ 379 1 4 CH(CH₃)₂ 380 1 3 S CH(CH₃)₂ 381 1 3 CH₂ CH(CH₃)₂ 382 2 3 S H 383 2 4 H 384 2 3 CH₂ H 385 2 4 H 386387388389390391392393 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

394 1 4 CH₂ CH₃ 395 1 4 CH(CH₃)₂ 396 1 3 S CH(CH₃)₂ 397 1 3 CH₂ CH(CH₃)₂ 398 2 3 S H 399 2 4 H 400 2 3 CH₂ H 401 2 4 H 402403404405406407 111111 343434 S CH₂ CF₂ HHHHHH

408 1 4 S CH₃ 409 1 4 CH(CH₃)₂ 410 1 4 CH₂ CH₃ 411 1 4 CH(CH₃)₂ 412 1 3 S CH(CH₃)₂ 413 1 3 CH₂ CH(CH₃)₂ 414 2 3 S H 415 2 4 H 416 2 3 CH₂ H 417 2 4 H 418419420421422423424425 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

426 1 4 CH₂ CH₃ 427 1 4 CH(CH₃)₂ 428 1 3 S CH(CH₃)₂ 429 1 3 CH₂ CH(CH₃)₂ 450 2 3 S H 451 2 4 H 452 2 3 CH₂ H 453 2 4 H 454455456457458459 111111 343434 S CH₂ CF₂ HHHHHH

460 1 4 S CH₃ 461 1 4 CH(CH₃)₂ 462 1 4 CH₂ CH₃ 463 1 4 CH(CH₃)₂ 464 1 3 S CH(CH₃)₂ 465 1 3 CH₂ CH(CH₃)₂ 466 2 3 S H 467 2 4 H 468 2 3 CH₂ H 469 2 4 H 470471472473474475476477 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

478 1 4 CH₂ CH₃ 479 1 4 CH(CH₃)₂ 480 1 3 S CH(CH₃)₂ 481 1 3 CH₂ CH(CH₃)₂ 482 2 3 S H 483 2 4 H 484 2 3 CH₂ H 485 2 4 H 486487488489490491 111111 343434 S CH₂ CF₂ HHHHHH

492 1 4 S CH₃ 493 1 4 CH(CH₃)₂ 494 1 4 CH₂ CH₃ 495 1 4 CH(CH₃)₂ 496 1 3 S CH(CH₃)₂ 497 1 3 CH₂ CH(CH₃)₂ 498 2 3 S H 499 2 4 H 500 2 3 CH₂ H 501 2 4 H 502503504505506507508509 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

510 1 4 CH₂ CH₃ 511 1 4 CH(CH₃)₂ 512 1 3 S CH(CH₃)₂ 513 1 3 CH₂ CH(CH₃)₂ 514 2 3 S H 515 2 4 H 516 2 3 CH₂ H 517 2 4 H 518519520521522523524525 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

526 1 4 CH₂ CH₃ 527 1 4 CH(CH₃)₂ 528 1 3 S CH(CH₃)₂ 529 1 3 CH₂ CH(CH₃)₂ 530 2 3 S H 531 2 4 H 532 2 3 CH₂ H 533 2 4 H 534535536537538539540541 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

542 1 4 CH₂ CH₃ 543 1 4 CH(CH₃)₂ 544 1 3 S CH(CH₃)₂ 545 1 3 CH₂ CH(CH₃)₂ 546 2 3 S H 547 2 4 H 548 2 3 CH₂ H 549 2 4 H 550551552553554555556557 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

558 1 4 CH₂ CH₃ 559 1 4 CH(CH₃)₂ 560 1 3 S CH(CH₃)₂ 561 1 3 CH₂ CH(CH₃)₂ 562 2 3 S H 563 2 4 H 564 2 3 CH₂ H 565 2 4 H 566567568569570571572573 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

574 1 4 CH₂ CH₃ 575 1 4 CH(CH₃)₂ 576 1 3 S CH(CH₃)₂ 577 1 3 CH₂ CH(CH₃)₂ 578 2 3 S H 579 2 4 H 580 2 3 CH₂ H 581 2 4 H 582583584585586587588589 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

590 1 4 CH₂ CH₃ 591 1 4 CH(CH₃)₂ 592 1 3 S CH(CH₃)₂ 593 1 3 CH₂ CH(CH₃)₂ 594 2 3 S H 595 2 4 H 596 2 3 CH₂ H 597 2 4 H 598599600601602603604605 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

606 1 4 CH₂ CH₃ 607 1 4 CH(CH₃)₂ 608 1 3 S CH(CH₃)₂ 609 1 3 CH₂ CH(CH₃)₂ 610 2 3 S H 611 2 4 H 612 2 3 CH₂ H 613 2 4 H 614615616617618619620621 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

622 1 4 CH₂ CH₃ 623 1 4 CH(CH₃)₂ 624 1 3 S CH(CH₃)₂ 625 1 3 CH₂ CH(CH₃)₂ 626 2 3 S H 627 2 4 H 628 2 3 CH₂ H 629 2 4 H 630631632633634635636637 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

638 1 4 CH₂ CH₃ 639 1 4 CH(CH₃)₂ 640 1 3 S CH(CH₃)₂ 641 1 3 CH₂ CH(CH₃)₂ 642 2 3 S H 643 2 4 H 644 2 3 CH₂ H 645 2 4 H 646647648649650651652653 11111111 34343444 S CH₂ CF₂ S HHHHHHCH(CH₃)₂CH₃

654 1 4 CH(CH₃)₂ CH2 655 1 3 S CH(CH₃)₂ 656 1 3 CH₂ CH(CH₃)₂ 657 2 3 S H 658 2 4 H 659 2 3 CH₂ H 660 2 4 H 661662663664665666667668 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

669 1 4 CH₂ CH₃ 670 1 4 CH(CH₃)₂ 671 1 3 S CH(CH₃)₂ 672 1 3 CH₂ CH(CH₃)₂ 673 2 3 S H 674 2 4 H 675 2 3 CH₂ H 676 2 4 H 677678679680681682 111111 343444 SCH₂CF₂ S HHHHCH₃CH(CH₃)₂

683 1 4 CH₂ CH₃ 684 1 4 CH(CH₃)₂ 685 1 3 S CH(CH₃)₂ 686 1 3 CH₂ CH(CH₃)₂ 687 2 3 S H 688 2 4 CH₂ H 689690691692693694695696 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

697 1 4 CH₂ CH₃ 698 1 4 CH(CH₃)₂ 699 1 3 S CH(CH₃)₂ 700 1 3 CH₂ CH(CH₃)₂ 701 2 3 S H 702 2 4 H 703 2 3 CH₂ H 704 2 4 H 705706707708709 11111 34343 S CH₂ CF₂ HHHHH

710 1 4 H 711 1 4 S CH₃ 712 1 4 CH(CH₃)₂ 713 1 4 CH₂ CH₃ 714 1 4 CH(CH₃)₂ 715 1 3 S CH(CH₃)₂ 716 1 3 CH₂ CH(CH₃)₂ 717 2 3 S H 718 2 4 H 719 2 3 CH₂ H 720 2 4 H 721722723724725726727728 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

729 1 4 CH₂ CH₃ 730 1 4 CH(CH₃)₂ 731 1 3 S CH(CH₃)₂ 732 1 3 CH₂ CH(CH₃)₂ 733 2 3 S H 734 2 4 H 735 2 3 CH₂ H 736 2 4 H 737738739740741 11111 33434 SCH₂ CF₂ HHHHH

742 1 4 S CH₃ 743 1 4 CH(CH₃)₂ 744 1 4 CH₂ CH₃ 745 1 4 CH(CH₃)₂ 746 1 3 S CH(CH₃)₂ 747 1 3 CH₂ CH(CH₃)₂ 748 2 3 S H 749 2 4 H 750 2 3 CH₂ H 751 2 4 H 752753754755756757758759 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

760 1 4 CH₂ CH₃ 761 1 4 CH(CH₃)₂ 762 1 3 S CH(CH₃)₂ 763 1 3 CH₂ CH(CH₃)₂ 764 2 3 S H 765 2 4 H 766 2 3 CH₂ H 767 2 4 H 768769770771772773 11111 343434 S CH₂ CF₂ HHHHHH

774 1 4 S CH₃ 775 1 4 CH(CH₃)₂ 776 1 4 CH₂ CH₃ 777 1 4 CH(CH₃)₂ 778 1 3 S CH(CH₃)₂ 779 1 3 CH₂ CH(CH₃)₂ 780 2 3 S H 781 2 4 H 782 2 3 CH₂ H 783 2 4 H 784785786787788789790791 11111111 34343444 S CH₂ CF₂ S HHHHHHCH₃CH(CH₃)₂

792 1 4 CH₂ CH₃ 793 1 4 CH(CH₃)₂ 794 1 3 S CH(CH₃)₂ 795 1 3 CH₂ CH(CH₃)₂ 796 2 3 S H 797 2 4 H 798 2 3 CH₂ H 799 2 4 H

TABLE 4

Example No X R 800801 SCH₂

802803 SCH₂

804805 SCH₂

806807 SCH₂

808809 SCH₂

810811 SCH₂

812813 SCH₂

814815 SCH₂

816817 SCH₂

818819 SCH₂

820821 SCH₂

822823 SCH₂

824825 SCH₂

826827 SCH₂

828829 SCH₂

830831 SCH₂

832833 SCH₂

834835 SCH₂

836837 SCH₂

838839 SCH₂

841842 SCH₂

843844 SCH₂

845846 SCH₂

847 SCH₂

848849 SCH₂

850851 SCH₂

852853 SCH₂

854855 SCH₂

856857 SCH₂

858859 SCH₂

860861 SCH₂

862863 SCH₂

864865 SCH₂

866867 SCH₂

868869 SCH₂

870871 SCH₂

872873 SCH₂

874875 SCH₂

876877 SCH₂

TABLE 5

Example No n X R 878879880881 3434 S CH₂ 

882883884885 3434 S CH₂ 

886887888889 3434 S CH₂ 

890891892893 3434 S CH₂ 

894895896897 3434 S CH₂ 

898899900901 3434 S CH₂ 

902903904905 3434 S CH₂ 

906907908909 3434 S CH₂ 

910911912913 3434 S CH₂ 

914915916917 3434 S CH₂ 

9189199200 3434 S CH₂ 

921922923924 3434 S CH₂ 

925926927928 3434 S CH₂ 

929930931932 3434 S CH₂  Me 933934935936 3434 S CH₂ 

937938939940 3434 S CH₂ 

941942943944 3434 S CH₂ 

945946 34 SCH₂

947948949950 3434 S CH₂ 

951952953954 3434 S CH₂ 

955956957958 3434 S CH₂ 

959960961962 3434 S CH₂ 

963964965966 3434 S CH₂ 

967968969970 3434 S CH₂ 

971972973974 3434 S CH₂ 

975976977978 4 34 S CH₂ 

979980981982 3434 S CH₂  MeS 983984985986 3434 S Ch₂  MeO

TABLE 6

Example No n X R 987988989990 3434 S CH₂ 

991992993994 4 34 S CH₂ 

997998999998 3434 S CH₂ 

999100010011002 3434 S CH₂ 

1003100410051006 3434 S CH₂ 

10071008 10091010 3434 S CH₂ 

1011101210131014 3434 S CH₂ 

1015101610171018 3434 S CH₂ 

1019102010211022 3434 S CH₂ 

1023102410251026 3434 S CH₂ 

1027102810291030 3434 S CH₂ 

1031103210331034 3434 S CH₂ 

1035103610371038 3434 S CH₂ 

1039104010411042 3434 S CH₂  Me 1044104510461047 3434 S CH₂ 

1048104910501051 3434 S CH₂ 

1052105310541055 3434 S CH₂ 

10561057 34 SCH₂

1058105910601061 3434 S CH₂ 

1062106310641065 3434 S CH₂ 

1066106710681069 3434 S CH₂ 

1070107110721073 3434 S CH₂ 

1074107510761077 3434 S CH₂ 

1078107910801081 3434 S CH₂ 

1082108310841085 3434 S CH₂ 

1086108710881089 3434 S CH₂ 

1090109110921093 3434 S CH₂  MeS 1094109510961097 3434 S CH₂  MeO

TABLE 7

Example No n X R 1098109911001101 3434 S CH₂ 

1102110311041105 3434 S CH₂ 

1106110711081109 3434 S CH₂ 

1110111111121113 3434 S CH₂ 

1114111511161117 3434 S CH₂ 

1118111911201121 3434 S CH₂ 

1122112311241125 3434 S CH₂ 

1125a112611271128 3434 S CH₂ 

1129113011311132 3434 S CH₂ 

1133113411351136 3434 S CH₂ 

1137113811391140 3434 S CH₂ 

1141114211431144 3434 S CH₂ 

1145114611471148 3434 S CH₂ 

1149115011511152 3434 S CH₂ 

1153115411551156 3434 S CH₂ 

11571158 34 SCH₂

1159116011611162 3434 S CH₂ 

1163116411651166 3434 S CH₂ 

1167116811691170 3434 S CH₂ 

1171117211731174 3434 S CH₂ 

1175117611771178 3434 S CH₂ 

1179118011811182 3434 S CH₂ 

1183118411851186 3434 S CH₂ 

TABLE 8

Example No n X R 1187118811891190 3434 S CH₂ 

1191119211931194 3434 S CH₂ 

1195119611971198 3434 S CH₂ 

1199120012011202 3434 S CH₂ 

1203120412051206 3434 S CH₂ 

1207120812091210 3434 S CH₂ 

1211121212131214 3434 S CH₂ 

1215121612171218 3434 S CH₂ 

1219122012211222 3434 S CH₂ 

1223122412251226 3434 S CH₂ 

1227122812291230 3434 S CH₂ 

1231123212331235 3434 S CH₂ 

1235123612371238 3434 S CH₂ 

1239124012411242 3434 S CH₂ 

1243124412451246 3434 S CH₂ 

12471248 34 SCH₂

1249125012511252 3434 S CH₂ 

1253125412551256 3434 S CH₂ 

1257125812591260 3434 S CH₂ 

1261126212631264 3434 S CH₂ 

1265126612671268 3434 S CH₂ 

1269127012711272 3434 S CH₂ 

1273127412751276 3434 S CH₂ 

Example 1277 1-[2-(S)-Amino-4-(cyclohexylmethylamino)butanoyl]thiomorpholine dihydrochloride

A. 1-[2-(S)—N-(tert-Butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoyl]thiomorpholine

1-[2-(S)—N-(tert-Butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoic acid (1.0 g, 2.27 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 20 mL). To this solution at 0° C. were added 1-hydroxybenzotriazole hydrate (461 mg, 3.41 mmol), water-soluble carbodiimide (521 mg, 2.72 mmol), thiomorpholine (281 mg, 2.72 mmol) and triethylamine (340 mg, 3.4 mmol). After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100 mL). The solution was washed with 0.3M KHSO₄ (2×25 mL), sat. NaHCO₃ (2×25 mL), water (2×25 mL) and brine (1×25 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a white solid identified as 1-[2-(S)—N-(tert-butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoyl]thiomorpholine (516 mg, 0.98 mmol, 43%).

B. 1-[2-(S)—N-(tert-Butyloxycarbonyl)-4-amino)-butanoyl]thiomorpholine

1-[2-(S)—N-(tert-Butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoyl thiomorpholine (500 mg, 0.95 mmol) was dissolved in tetrahydrofuran (20 mL). Diethylamine (5 mL) was added. After 90 min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 1-[2-(S)—N-(tert-butyloxycarbonyl)-4-amino)-butanoyl]thiomorpholine (162 mg, 0.54 mmol, 56%).

C. 1-[2-(S)—N-(tert-Butyloxycarbonyl)-amino-4-(cyclohexylmethylamino)butanoyl]thiomorpholine

1-[2-(S)—N-(tert-Butyloxycarbonyl)-4-amino)-butanoyl]thiomorpholine (41 mg, 0.135 mmol) was dissolved in dichloroethane (10 mL). To this solution was added cyclohexanecarboxaldehyde (15 mg, 0.135 mmol). After 30 mins sodium triacetoxyborohydride (32 mg, 0.15 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid, 9% methanol, 90% chloroform) to give a colourless oil identified as 1-[2-(S)—N-(tert-butyloxycarbonyl)-amino-4-(cyclohexylmethylamino)butanoyl]thiomorpholine (25 mg, 0.063 mmol, 47%).

D. 1-[2-(S)-Amino-4-(cyclohexylmethylamino)butanoyl]thiomorpholine dihydrochloride

1-[2-(S)—N-(tert-Butyloxycarbonyl)-amino-4-(cyclohexylmethylamino)butanoyl]thiomorpholine (25 mg, 0.063 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[2-(S)-amino-4-(cyclohexylmethylamino)butanoyl]thiomorpholine dihydrochloride (23 mg, 0.063 mmol, 100%).

[M+H]⁺=300.3

Example 1278 1-[2-(S)-Amino-4-((quinolin-2-ylmethyl)amino)butanoyl]thiomorpholine dihydrochloride

A. 1-[2-(S)—N-(tert-Butyloxycarbonyl)-amino-4-((quinolin-2-ylmethyl)amino)butanoyl thiomorpholine

1-[2-(S)—N-(tert-Butyloxycarbonyl)-4-amino)-butanoyl]thiomorpholine (41 mg, 0.135 mmol) was dissolved in 1,2-dichloroethane (10 mL). To this solution was added 2-quinolinecarboxaldehyde (32 mg, 0.15 mmol). After 30 mins sodium triacetoxyborohydride (36 mg, 0.17 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid, 9% methanol, 90% chloroform) to give a colourless oil identified as 1-[2-(S)—N-(tert-butyloxycarbonyl)-amino-4-((quinolin-2-ylmethyl)amino)butanoyl thiomorpholine (32 mg, 0.072 mmol, 53%).

B. 1-[2-(S)-Amino-4-((quinolin-2-ylmethyl)amino)butanoyl]thiomorpholine dihydrochloride

1-[2-(S)—N-(tert-Butyloxyarbonyl)-amino-4-((quinolin-2-ylmethyl)amino)butanoyl]thiomorpholine (12 mg, 0.027 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[2-(S)-amino-4-((quinolin-2-ylmethyl)amino)butanoyl]thiomorpholine dihydrochloride (11.3 mg, 0.027 mmol, 100%).

[M+H]⁺=345.3

Example 1279 1-[2-(S)-Amino-4-(cyclohexylmethylamino)butanoyl]piperidine dihydrochloride

A. 1-[2-(S)—N-(tert-Butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoyl]piperidine

1-[2-(S)—N-(tert-Butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoic acid (947 mg, 2.154 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 20 mL). To this solution at 0° C. were added 1-hydroxybenzotriazole hydrate (436 mg, 3.2 mmol), water-soluble carbodiimide (495 g, 2.58 mmol), piperidine (220 g, 2.58 mmol) and triethylamine (320 mg, 3.2 mmol). After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100 mL). The solution was washed with 0.3M KHSO₄ (2×25 mL), sat. NaHCO₃ (2×25 mL), water (2×25 mL) and brine (1×25 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a white solid identified as 1-[2-(S)—N-(tert-butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoyl]piperidine (556 mg, 1.1 mmol, 51%).

B. 1-[2-(S)—N-(tert-Butyloxycarbonyl)-4-amino)-butanoyl]piperidine

1-[2-(S)—N-(tert-Butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoyl]piperidine (540 g, 1.1 mmol) was dissolved in tetrahydrofuran (20 mL). Diethylamine (5 mL) was added. After 90 min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 1-[2-(S)—N-(tert-butyloxycarbonyl)-4-amino)-butanoyl]piperidine (171 mg, 0.6 mmol, 57%).

C. 1-[2-(S)—N-(tert-Butyloxycarbonyl)-amino-4-(cyclohexylmethylamino)butanoyl]piperidine

1-[2-(S)—N-(tert-Butyloxycarbonyl)-4-amino)-butanoyl]piperidine (43 mg, 0.15 mmol) was dissolved in 1,2-dichloroethane (20 mL). To this solution was added cyclohexanecarboxaldehyde (17 mg, 0.15 mmol). After 30 mins sodium triacetoxyborohydride (36 mg, 0.17 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid, 9% methanol, 90% chloroform) to give a colourless oil identified as 1-[2-(S)—N-(tert-butyloxycarbonyl)-amino-4-(cyclohexylmethylamino)butanoyl]piperidine (38 mg, 0.1 mmol, 66%).

D. 1-[2-(S)-Amino-4-(cyclohexylmethylamino)butanoyl]piperidine dihydrochloride

1-[2-(S)—N-(tert-Butyloxycarbonyl)-amino-4-(cyclohexylmethylamino)butanoyl]piperidine (38 mg, 0.1 mmol) was dissolved in 4M HCl/dioxan (2 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[2-(S)-amino-4-(cyclohexylmethylamino)butanoyl]piperidine dihydrochloride (33 mg, 0.093 mmol, 93%).

[M+H]⁺=282.3

Example 1280 1-[2-(S)-Amino-4-((quinolin-2-ylmethyl)amino)butanoyl]piperidine dihydrochloride

A. 1-[2-(S)—N-(tert-Butyloxycarbonyl)-amino-4-((quinolin-2-ylmethyl)amino)butanoyl]piperidine

1-[2-(S)—N-(tert-Butyloxycarbonyl)-4-amino)-butanoyl]piperidine (24 mg, 0.15 mmol) was dissolved in 1,2-dichloroethane (25 mL). To this solution was added 2-quinolinecarboxaldehyde (24 mg, 0.15 mmol). After 30 mins sodium triacetoxyborohydride (36 mg, 0.17 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid, 9% methanol, 90% chloroform) to give a colourless oil identified as 1-[2-(S)—N-(tert-butyloxycarbonyl)-amino-4-((quinolin-2-ylmethyl)amino)butanoyl]piperidine (35 mg, 0.082 mmol, 55%).

B. 1-[2-(S)-Amino-4-((quinolin-2-ylmethyl)amino)butanoyl]piperidine dihydrochloride

1-[2-(S)—N-(tert-Butyloxyarbonyl)-amino-4-((quinolin-2-ylmethyl)amino)butanoyl]piperidine (35 mg, 0.082 mmol) was dissolved in 4M HCl/dioxan (2 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[2-(S)-amino-4-((quinolin-2-ylmethyl)amino)butanoyl]piperidine dihydrochloride (26 mg, 0.065 mmol, 79%).

[M+H]⁺=327.3

Example 1281 3-Fluoro-1-[2-(S)-amino-4-(cyclohexenylmethylamino)butanoyl]pyrrolidine dihydrochloride

A. 1-(tert-Butyloxycarbonyl)-3-fluoropyrrolidine

N-(tert-Butyloxycarbonyl)-3-hydroxypyrrolidine (21.0 g, 10.7 mmol) was dissolved in CH₂Cl₂ (30 ml). (Diethylamino)sulphur trifluoride (1.72 g, 10.7 mmol) was added to this solution at −78° C. The mixture was stirred for 18 hours at −78° C. to room temperature then the reaction mixture was carefully poured into sat. NaHCO₃ (100 ml) and stirred for 15 min and extracted with CH₂Cl₂. The organic extract was washed with water and brine, dried (Na₂SO₄) and evaporated in vacuo to give an orange oil. The residue was purified by flash chromatography (eluant: 28% ethyl acetate, 72% pet. ether 60-80) to give a colourless oil identified as 1-(tert-butyloxycarbonyl)-3-fluoropyrrolidine (1.14 g, 5.34 mmol, 50%).

B 3-Fluoropyrrolidine hydrochloride

1-(tert-Butyloxycarbonyl)-3-fluoropyrrolidine (1.14 g, 5.34 mmol) was dissolved in 4M HCl/dioxan (30 ml). The mixture was stirred for 1 hour at room temperature then the solvent was removed in vacuo to give an off-white solid identified as 3-fluoropyrrolidine hydrochloride (640 mg, 5.2 mmol, 95%).

C. 3-Fluoro-1-[2-(S)—N-(tert-butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoyl]pyrrolidine

1-[2-(S)—N-(tert-Butyloxyarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoic acid (950 mg, 2.15 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 20 mL). To this solution at 0° C. were added 1-hydroxybenzotriazole hydrate (395 mg, 2.6 mmol), water-soluble carbodiimide (572 mg, 3.0 mmol), 3-fluoropyrrolidine hydrochloride (270 g, 2.15 mmol) and triethylamine (320 mg, 3.2 mmol). After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100 mL). The solution was washed with 0.3M KHSO₄ (2×25 mL), sat. NaHCO₃ (2×25 mL), water (2×25 mL) and brine (1×25 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a white solid identified as 3-fluoro1-[2-(S)—N-(tert-butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoyl]pyrrolidine (808 mg, 1.58 mmol, 73%).

D. 3-Fluoro-1-[2-(S)—N-(tert-butyloxycarbonyl)-4-amino)-butanoyl]pyrrolidine

3-Fluoro-1-[2-(S)—N-(tert-butyloxycarbonyl)amino-4-(9-fluorenylmethyloxycarbonylamino)-butanoyl]pyrrolidine (800 mg, 1.58 mmol) was dissolved in tetrahydrofuran (20 mL). Diethylamine (5 mL) was added. After 90 min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 3-fluoro-1-[2-(S)—N-(tert-butyloxycarbonyl)-4-amino)-butanoyl]pyrrolidine (316 mg, 1.04 mmol, 66%).

E. 3-Fluoro-1-[2-(S)—N-(tert-butyloxycarbonyl)-amino-4-(cyclohexenylmethylamino)butanoyl]pyrrolidine

3-Fluoro-1-[2-(S)—N-(tert-butyloxycarbonyl)-4-amino)-butanoyl]pyrrolidine (150 mg, 0.52 mmol) was dissolved in methanol (20 mL). To this solution was added 3-cyclohexanecarboxaldehyde (63 mg, 0.57 mmol). After 30 mins sodium triacetoxyborohydride (220 mg, 1.04 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid, 9% methanol, 90% chloroform) to give a colourless oil identified as 3-fluoro-1-[2-(S)—N-(tert-butyloxycarbonyl)-amino-4-(cyclohexenylmethylamino)butanoyl]pyrrolidine (176 mg, 0.46 mmol, 77%).

F. 3-Fluoro-1-[2-(S)-amino-4-(cyclohexenylmethylamino)butanoyl]pyrrolidine dihydrochloride

3-Fluoro-1-[2-(S)—N-(tert-butyloxycarbonyl)-amino-4-(cyclohexenylmethylamino)butanoyl]pyrrolidine (176 mg, 0.46 mmol) was dissolved in 4M HCl/dioxan (2 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 3-fluoro-1-[2-(S)-amino-4-(cyclohexenylmethylamino)butanoyl]pyrrolidine dihydrochloride (140 mg, 0.39 mmol, 963%).

[M+H]⁺=284.3

Example 1282 1-[2-(S)-Amino-4-(N-methyl-N-(2-methylbenzyl)amino)butanoyl]piperidine dihydrochloride

A. N-(tert-Butyloxycarbonyl)-L-homoserine lactone

L-Homoserine lactone 1.76 g, 12.8 mmol) was dissolved in DMF (30 mL). This solution was cooled to 0° C., triethylamine (1.41, 14.1 mmol) di-tert-butyl dicarbonate (3.35 g, 15.35 mmol) was added. After 18 hours at room temperature the solvent was evaporated in vacuo, the residue was taken up in dichloromethane (200 mL). This solution was washed with 1M KHSO₄ (2×50 mL) and brine (1×50 mL), dried (Na₂SO₄) and evaporated in vacuo to give a white solid, recrystallised from EtOAc/pet ether to give a white solid identified as N-(tert-butyloxycarbonyl)L-homoserine lactone (2.25 mg, 11.2 mmol, 87%).

B. 1-[2-(S)—(N-(tert-Butyloxycarbonyl)amino)-4-hydroxybutanoyl]piperidine

N-(tert-Butyloxycarbonyl)-L-homoserine lactone (100 mg, 0.5 mmol) was dissolved in tetrahydrofuran (30 mL). Piperidine (42 mg, 0.5 mmol) was added. After 72 hours at room temperature the reaction mixture was diluted with ethyl acetate (150 mL). This solution was washed with water (1×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil identified as 1-[2-(S)—(N-(tert-butyloxycarbonyl)amino)-4-hydroxybutanoyl]piperidine (142 mg, 0.5 mmol, 100%).

C. 1-[2-(S)—(N-(tert-Butyloxycarbonyl)amino)-4-oxobutanoyl]piperidine

1-[2-(S)—(N-(tert-Butyloxycarbonyl)amino)-4-hydroxybutanoyl]piperidine (142 mg, 0.5 mmol) was dissolved in dichloromethane (50 mL). Dess-Martin periodinane (232 mg, 0.5 mmol) was added. After 1 hour at room temperature the reaction mixture was diluted with ethyl acetate (150 mL). This solution was washed with water (1×20 ml) and brine (1×20 ml), dried (Na₂SO₄) and evaporated in vacuo to give a colourless oil. Purified by flash chromatography on silica gel (eluant: 50% ethyl acetate, 50% pet. ether 60-80) to give a colourless oil identified as 1-[2-(S)—(N-(tert-butyloxycarbonyl)amino)-4-oxobutanoyl]piperidine (40 mg, 0.14 mmol, 27%).

D. 1-[2-(S)—(N-(tert-butyloxycarbonyl)amino-4-(N-methyl-N-(2-methylbenzyl)amino) butanoyl]piperidine

1-[2-(S)—(N-(tert-Butyloxycarbonyl)amino)-4-oxobutanoyl]piperidine (40 mg, 14 mmol) was dissolved in methanol (20 mL). To this solution was added N-methyl-2-methylbenzylamine (19 mg, 0.14 mmol). After 2 hours sodium triacetoxyborohydride (64 mg, 0.3 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel to give a colourless oil identified as 1-[2-(S)—(N-(tert-butyloxycarbonyl)amino-4-(N-methyl-N-(2-methylbenzyl)amino) butanoyl]piperidine (36 mg, 0.09 mmol, 64%).

E. 1-[2-(S)-Amino-4-(N-methyl-N-(2-methylbenzyl)amino)butanoyl]piperidine dihydrochloride

1-[2-(S)—(N-(tert-Butyloxycarbonyl)amino-4-(N-methyl-N-(2-methylbenzyl)amino) butanoyl]piperidine (36 mg, 0.09 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pale brown solid identified as 1-[2-(S)-amino-4-(N-methyl-N-(2-methylbenzyl)amino)butanoyl]piperidine dihydrochloride (43 mg, 0.09 mmol, 100%).

Example 1283 1-[N-(2″-(Cyclohexylmethylaminoethyl)glycinyl)]thiomorpholine dihydrochloride

A. 1-[N-2′-(tert-Butyloxycarbonyl)-N-(2″-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycinyl]thiomorpholine

N-2′-(tert-Butyloxycarbonyl)-N-(2″-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycine (2.5 g, 5.7 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 100 mL). To this solution at 0° C. were added 1-hydroxybenzotriazole hydrate (833 mg, 6.3 mmol), water-soluble carbodiimide (974 mg, 6.3 mmol), thiomorpholine (617 mg, 6.0 mmol) and N-methylmorpholine (800 mg, 8 mmol). After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100 mL). The solution was washed with 0.3M KHSO₄ (2×25 mL), sat. NaHCO₃ (2×25 mL), water (2×25 mL) and brine (1×25 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a white solid identified as 1-[N-2′-(tert-butyloxycarbonyl)-N-(2″-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycinyl]thiomorpholine (2.7 g, 5.1 mmol, 90%).

B. 1-[N-2′-(tert-Butyloxycarbonyl)-(2″-aminoethyl)-glycinyl]thiomorpholine

1-[N-2′-(tert-Butyloxycarbonyl)-N-(2″-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycinyl]thiomorpholine (2.7 g, 5.1 mmol) was dissolved in tetrahydrofuran (20 mL). Diethylamine (5 mL) was added. After 90 min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 1-[N-2′-(tert-butyloxycarbonyl)-(2″-aminoethyl)-glycinyl]thiomorpholine (1.44 g, 4.7 mmol, 92%).

C. 1-[2′-N-(tert-Butyloxycarbonyl N-(2″-(cyclohexylmethylaminoethyl)-glycinyl]thiomorpholine

1-[N-2′-(tert-Butyloxycarbonyl)-(2″-aminoethyl)-glycinyl]thiomorpholine (100 mg, 0.3 mmol) was dissolved in methanol (25 mL). To this solution was added cyclohexanecarboxaldehyde (34 mg, 0.3 mmol). After 30 mins sodium triacetoxyborohydride (126 mg, 0.6 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid, 9% methanol, 90% chloroform) to give a colourless oil identified as 1-[2′-N-(tert-Butyloxycarbonyl N-(2″-(cyclohexylmethylaminoethyl)-glycinyl]thiomorpholine (33 mg, 0.08 mmol, 27%).

D. 1-[N-(2″-(Cyclohexylmethylaminoethyl)glycinyl)]thiomorpholine dihydrochloride

1-[2′-N-(tert-Butyloxycarbonyl-N-(2″-(cyclohexylmethylaminoethyl)-glycinyl]thiomorpholine (33 mg, 0.081 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[N-(2″-(cyclohexylmethylaminoethyl)glycinyl)]thiomorpholine dihydrochloride (31 mg, 0.08 mmol, 100%).

[M+H]⁺=300.3

Example 1284 1-[N-(2″-((Quinolin-2-ylmethyl)aminoethyl)glycinyl)]pyrrolidine dihydrochloride

A. 1-[N-2′-(tert-Butyloxycarbonyl)-N-(2″-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycinyl]piperidine

N-2′-(tert-Butyloxycarbonyl)-N-(2″-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycine (2.5 g, 5.7 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 100 mL). To this solution at 0° C. were added 1-hydroxybenzotriazole hydrate (1.5 g, 11.1 mmol), water-soluble carbodiimide (1.3 g, 6.8 mmol), piperidine (484 mg, 5.69 mmol) and N-methylmorpholine (800 mg, 8 mmol). After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100 mL). The solution was washed with 0.3M KHSO₄ (2×25 mL), sat. NaHCO₃ (2×25 mL), water (2×25 mL) and brine (1×25 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a white solid identified as 1-[N-2′-(tert-butyloxycarbonyl)-N-(2″-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycinyl]piperidine (2.8 g, 5.5 mmol, 96%).

B. 1-[N-2′-(tert-Butyloxycarbonyl)-(2″-aminoethyl)-glycinyl]piperidine

1-[N-2′-(tert-Butyloxycarbonyl)-N-(2″-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycinyl]piperidine (2.8 g, 5.5 mmol) was dissolved in tetrahydrofuran (20 mL). Diethylamine (5 mL) was added. After 90 min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 1-[N-2′-(tert-butyloxycarbonyl)-(2″-aminoethyl)-glycinyl]piperidine (1.4 g, 4.9 mmol, 89%).

C. 1-[2′-N-(tert-Butyloxycarbonyl N-(2″-((quinolin-2-ylmethyl)aminoethyl)-glycinyl]piperidine

1-[N-2′-(tert-Butyloxycarbonyl)-(2″-aminoethyl)-glycinyl]piperidine was dissolved in methanol (25 mL). To this solution was added 2-quinolinecarboxaldehyde. After 30 mins sodium triacetoxyborohydride was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 1% acetic acid, 9% methanol, 90% chloroform) to give a colourless oil identified as 1-[2′-N-(tert-butyloxycarbonyl N-(2″-((quinolin-2-ylmethyl)aminoethyl)-glycinyl]piperidine.

D. 1-[N-(2″-((Quinolin-2-ylmethyl)aminoethyl)glycinyl)]piperidine dihydrochloride

1-[2′-N-(tert-Butyloxycarbonyl-N-(2″-((quinolin-2-ylmethyl)aminoethyl)-glycinyl]piperidine was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[N-(2″-((quinolin-2-ylmethyl)aminoethyl)glycinyl)]piperidine dihydrochloride.

Example 1285 1-[N,N-(2″,2″-((Dicinnamyl)aminoethyl)glycinyl)]thiomorpholine dihydrochloride

A. 1-[2′-N-(tert-Butyloxycarbonyl N,N-(2″,2″-((dicinnamyl)aminoethyl)-glycinyl]thiomorpholine

(2S)-1-(N^(α)-(tert-Butyloxycarbonyl)-L-lysinyl)-pyrrolidine-2-carbonitrile (250 mg, 0.83 mmol) was dissolved in dichloroethane (25 mL). To this solution was added trans-cinnamaldehyde (108 mg, 0.83 mmol). After 30 mins sodium triacetoxyborohydride (350 mg, 1.6 mmol) was added. After 18 h at room temperature the solvent was removed in vacuo and the residue was taken up in chloroform (70 mL). This solution was washed with water (2×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography on silica gel (eluant: 2% methanol, 98% chloroform) to give a colourless oil identified as 1-[2′-N-(tert-butyloxycarbonyl N,N-(2″,2″-((dicinnamyl)aminoethyl)-glycinyl]thiomorpholine. Further elution with 9% methanol, 90% chloroform and 1% acetic acid gave a colourless oil identified as 1-[2′-N-(tert-butyloxycarbonyl N-(2″-((cinnamyl)aminoethyl)-glycinyl]thiomorpholine (180 mg, 0.43 mmol, 52%).

B. 1-[N,N-(2″,2″-((Dicinnamyl)aminoethyl)glycinyl)]thiomorpholine dihydrochloride

1-[2′-N-(tert-Butyloxycarbonyl N,N-(2″,2″-((dicinnamyl)aminoethyl)-glycinyl]thiomorpholine was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[N,N-(2″,2″-((dicinnamyl)aminoethyl)glycinyl)]thiomorpholine dihydrochloride.

Example 1286 1-[N-(2″-((Cinnamyl)aminoethyl)glycinyl)]thiomorpholine dihydrochloride

A. 1-[N-(2″-((Cinnamyl)aminoethyl)glycinyl)]thiomorpholine dihydrochloride

1-[2′-N-(tert-Butyloxycarbonyl N-(2″-((cinnamyl)aminoethyl)-glycinyl]thiomorpholine (180 mg, 0.43 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[N-(2″-((cinnamyl)aminoethyl)glycinyl)]thiomorpholine dihydrochloride (168 mg, 0.43 mmol, 100%).

[M+H]⁺=320.3

Example 1287 3,3-Difluoro-1-[N-2″-(3′-trifluoromethylanilino)pyridyl-3-carbonyl aminoethyl)glycinyl)]pyrrolidine dihydrochloride

A. 3,3-Difluoro-1-[N-2′-(tert-butyloxycarbonyl)-N-(2″-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycinyl]pyrrolidine

N-2′-(tert-Butyloxycarbonyl)-N-(2″-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycine (1.0 g, 2.27 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 100 mL). To this solution at 0° C. were added 1-hydroxybenzotriazole hydrate (620 mg, 4.6 mmol), water-soluble carbodiimide (560 mg, 2.8 mmol), 3,3-difluoropyrrolidine hydrochloride (360 mg, 2.5 mmol) and N-methylmorpholine (800 mg, 8 mmol). After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (100 mL). The solution was washed with 0.3M KHSO₄ (2×25 mL), sat. NaHCO₃ (2×25 mL), water (2×25 mL) and brine (1×25 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 60% ethyl acetate, 40% pet. ether) to give a white solid identified as 3,3-difluoro-1-[N-2′-(tert-butyloxycarbonyl)-N-(2″-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycinyl]pyrrolidine (934 g, 1.7 mmol, 77%).

B. 3,3-Difluoro-1-[N-2′-(tert-butyloxycarbonyl)aminoethyl)-glycinyl]pyrrolidine

3,3-Difluoro-1-[N-2′-(tert-butyloxycarbonyl)-N-(2″-(9-fluorenylmethyloxycarbonyl aminoethyl)-glycinyl]pyrrolidine (890 g, 1.68 mmol) was dissolved in tetrahydrofuran (20 mL). Diethylamine (5 mL) was added. After 90 min at room temperature the solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant: 90% chloroform, 7% methanol, 3% triethylamine) to give a pale yellow oil identified as 3,3-difluoro-1-[N-2′-(tert-butyloxycarbonyl)aminoethyl)-glycinyl]pyrrolidine (470 mg, 1.5 mmol, 91%).

C. 3,3-Difluoro-1-[N-2′-(tert-butyloxycarbonyl)-N-2″-(3′-trifluoromethylanilino)pyridyl-3-carbonyl aminoethyl)glycinyl)]pyrrolidine

3,3-Difluoro-1-[N-2′-(tert-butyloxycarbonyl)aminoethyl)-glycinyl]pyrrolidine (50 mg, 0.16 mmol) was dissolved in CH₂Cl₂/DMF (9:1, 20 mL). To this solution at 0° C. was added 1-hydroxybenzotriazole hydrate (46 mg, 0.34 mmol), water-soluble carbodiimide (40 mg, 0.2 mmol), niflumic acid (49 mg, 0.17 mmol) and N-methylmorpholine (40 mg, 0.4 mmol). After 18 h at 0° C. to room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (70 mL). The solution was washed with 0.3M KHSO₄ (1×20 mL), sat. NaHCO₃ (1×20 mL), water (1×20 mL) and brine (1×20 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant: 75% ethyl acetate, 25% pet. ether) to give a yellow oil identified as 3,3-difluoro-1-[N-2′-(tert-butyloxycarbonyl)-N-2″-(3′-trifluoromethylanilino)pyridyl-3-carbonyl aminoethyl)glycinyl)]pyrrolidine (63 mg, 0.11 mmol, 67%).

D. 3,3-Difluoro-1-[N-2″-(3′-trifluoromethylanilino)pyridyl-3-carbonyl aminoethyl) glycinyl)]pyrrolidine dihydrochloride

3,3-Difluoro-1-[N-2′-(tert-butyloxycarbonyl)-N-2″-(3′-trifluoromethylanilino)pyridyl-3-carbonyl aminoethyl)glycinyl)]pyrrolidine (55 mg, 0.10 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a pale brown solid identified as 3,3-difluoro-1-[N-2″-(3′-trifluoromethylanilino)pyridyl-3-carbonyl aminoethyl)glycinyl)]pyrrolidine dihydrochloride (52 mg, 0.10 mmol, 100%).

[M+H]⁺=472.3

Example 1288 3,3-Difluoro-[N-2″-(6-Chloro-4-(4′-fluoroanilino)-1,3,5-triazinyl)aminoethyl) glycinyl)]thiomorpholine dihydrochloride

A. 4,6-Dichloro-2-(4′-fluoroanilino)-1,3,5-triazine

Cyanuric chloride (1.844 g, 10 mmol) was dissolved in acetonitrile (20 mL). The solution was cooled to −20° C. A solution of 4-fluoroaniline (1.1 g, 10 mmol) and triethylamine (1.0 g, 10 mmol) was slowly added. After 1 hour at −20° C. the solvent was removed in vacuo and the residue was taken up in ethyl acetate (150 mL). The solution was washed with water (1×50 mL) and brine (1×50 mL), dried (Na₂SO₄) and evaporated in vacuo. The residue was recrystallised from ethyl acetate/hexane to give an off white solid identified as 4,6-dichloro-2-(4′-fluoroanilino)-1,3,5-triazine 1.7 g, 6.0 mmol, 60%).

B. 1-[N-2′-(tert-butyloxycarbonyl)-N-2″-(6-Chloro-4-(4′-fluoroanilino)-1,3,5-triazinyl aminoethyl)glycinyl)]thiomorpholine

1-[N-2′-(tert-butyloxycarbonyl)aminoethyl)-glycinyl]thiomorpholine (100 mg, 0.3 mmol) was dissolved in dichloromethane (30 mL). To this solution was added 4,6-dichloro-2-(4′-fluoroanilino)-1,3,5-triazine (90 mg, 0.3 mmol) and triethylamine (50 mg, 0.5 mmol). After 2 hours at room temperature the solvent was removed in vacuo and the residue was taken up in ethyl acetate (150 mL). This solution was washed with water (2×30 mL) and brine (1×30 mL), dried (Na₂SO₄) and evaporated in vacuo to give a yellow oil. The residue was purified by flash chromatography (eluant: 60% ethyl acetate, 40% pet. ether) to give a white solid identified as 1-[N-2′-(tert-butyloxycarbonyl)-N-2″-(6-chloro-4-(4′-fluoroanilino)-1,3,5-triazinyl aminoethyl)glycinyl)]thiomorpholine (20 mg, 0.032 mmol, 11%).

C. 1-[N-2″-(6-Chloro-4-(4′-fluoroanilino)-1,3,5-triazinyl)aminoethyl)glycinyl)]thiomorpholine dihydrochloride

1-[N-2′-(tert-butyloxycarbonyl)-N-2″-(6-chloro-4-(4′-fluoroanilino)-1,3,5-triazinyl aminoethyl)glycinyl)]thiomorpholine (18.8 mg, 0.03 mmol) was dissolved in 4M HCl/dioxan (20 mL). After 1 h at room temperature the solvent was removed in vacuo. The residue was lyophilised from water to give a white solid identified as 1-[N-2″-(6-Chloro-4-(4′-fluoroanilino)-1,3,5-triazinyl)aminoethyl)glycinyl)]thiomorpholine dihydrochloride (18 mg, 0.03 mmol, 100%).

[M+H]⁺=526.4

TABLE 9

Ex No X a R 128912901291129212931294 SCF₂CHFSCH₂O 1  2

129512961297129812991300 SCF₂CHFSCH₂O 1  2

131113121313131413151316 SCF₂CHFSCH₂O 1  2

1317131813191320 SCF₂CHFO 1  2

132113221323132413251326 SCF₂CHFSCH₂O 1  2

132713281329133013311332 SCF₂CHFSCH₂O 1  2

133313341335133613371338 SCF₂CHFSCH₂O 1  2

133913401341134213431344 SCF₂CHFSCH₂O 1  2

134513461347134813491350 SCF₂CHFSCH₂O 1  2

135113521353135413551356 SCF₂CHFSCH₂O 1  2

135713581359136013611362 SCF₂CHFSCH₂O 1  2

136313641365136613671368 SCF₂CHFSCH₂O 1  2

136913701371137213731374 SCF₂CHFSCH₂O 1  2

137513761377137813791380 SCF₂CHFSCH₂O 1  2

138113821383138413851386 SCF₂CHFSCH₂O 1  2

138713881389139013911392 SCF₂CHFSCH₂O 1  2

139313941395139613971398 SCF₂CHFSCH₂O 1  2

139914001401140214031404 SCF₂CHFSCH₂O 1  2

140514061407140814091410 SCF₂CHFSCH₂O 1  2

141114121413141414151416 SCF₂CHFSCH₂O 1  2

141714181419142014211422 SCF₂CHFSCH₂O 1  2

142314241425142614271428 SCF₂CHFSCH₂O 1  2

142914301431143214331434 SCF₂CHFSCH₂O 1  2

TABLE 10

Ex No X a R 1614161516161617 SCF₂SCH₂ 1 2

1618161916201621 SCF₂SCH₂ 1 2

1622162316241625 SCF₂SCH₂ 1 2

1626162716281629 SCF₂SCH₂ 1 2

1630163116321633 SCF₂SCH₂ 1 2

1634163516361637 SCF₂SCH₂ 1 2

1638163916401641 SCF₂SCH₂ 1 2

1642164316441645 SCF₂SCH₂ 1 2

1646164716481649 SCF₂SCH₂ 1 2

1650165116521653 SCF₂SCH₂ 1 2

1654165516561657 SCF₂SCH₂ 1 2

1658165916601661 SCF₂SCH₂ 1 2

1662166316641665 SCF₂SCH₂ 1 2

1666166716681669 SCF₂SCH₂ 1 2

1670167116721673 SCF₂SCH₂ 1 2

1674167516761677 SCF₂SCH₂ 1 2

1678167916801681 SCF₂SCH₂ 1 2

1682168316841685 SCF₂SCH₂ 1 2

1686168716881689 SCF₂SCH₂ 1 2

1690169116921693 SCF₂SCH₂ 1 2

1694169516961697 SCF₂SCH₂ 1 2

1698169917001701 SCF₂SCH₂ 1 2

1702170317041705 SCF₂SCH₂ 1 2 

1. A compound according to general formula 1, or a pharmaceutically acceptable salt thereof,

wherein: either G¹ is —CH₂—X²—(CH₂)_(a)-G³ and G² is H, or G² is —CH₂—(CH₂)_(a)-G³ and G¹ is H; G³ is selected from a group according to general formula 2, a group according to general formula 3, and a group according to general formula 4;

a is 0, 1 or 2; b is 1 or 2; X¹ is selected from CH₂, S, CF₂, CHF, CH(CH₃), C(CH₃)₂, CH(CN) and O; X² is selected from CH₂, O and S, provided that if a is 1 then X² is CH₂; X³, X⁴ and X⁵ are selected from N and CH, provided that at least two of X³, X⁴ and X⁵ are N; X⁶ is selected from O and NH; X⁷ is selected from CH₂, O, S and NH; R¹ is selected from H and CN; R² is selected from H and alkyl; R³ is selected from H, Cl, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂; R⁴, R⁵, R⁶, R⁷ and R⁸ are independently selected from H, Br, Cl, F, CF₃, alkyl, acyl, OH, O-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NO₂, NH-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂ and CN; R⁹ is selected from H and alkyl; R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ are independently selected from H, Br, Cl, F, CF₃, alkyl, acyl, OH, O-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NO₂, NH-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂ and CN; R¹⁵ and R¹⁶ are independently selected from H, alkyl, alkenyl, polyfluoroalkyl, aralkyl, aryl and —CH₂-L-R⁷, or R¹⁵ and R¹⁶ together form a group according to general formula 5, general formula 6 or general formula 7;

R¹⁷ is selected from H, alkyl and aryl; R¹⁸ is selected from H, alkyl, aryl, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂; R¹⁹ is selected from H, alkyl, aryl, F, Cl, Br, CF₃, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂; L is selected from a covalent bond, CH═CH, C≡C and —C₆H₄—; d and e are selected from 0, 1, 2 and 3 such that d+e is 3, 4 or 5; and f is selected from 1, 2 and 3; provided that when R¹⁵ and R¹⁶ are both H and b is 1 then X¹ is not S or CH₂.
 2. A compound according to general formula 8, or a pharmaceutically acceptable salt thereof,

wherein: a is 0, 1 or 2; b is 1 or 2; X¹ is selected from CH₂, S, CF₂, CHF, CH(CH₃), C(CH₃)₂, CH(CN) and O; X² is selected from CH₂, O and S, provided that if a is 1 then X² is CH₂; X³, X⁴ and X⁵ are selected from N and CH, provided that at least two of X³, X⁴ and X⁵ are N; X⁶ is selected from O and NH; R¹ is selected from H and CN; R² is selected from H and alkyl; R³ is selected from H, Cl, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂; R⁴, R⁵, R⁶, R⁷ and R⁸ are independently selected from H, Br, Cl, F, CF₃, alkyl, acyl, OH, O-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NO₂, NH-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂ and CN.
 3. A compound according to claim 2 wherein R¹ is H.
 4. A compound according to claim 2 wherein R¹ is CN.
 5. A compound according to any of claims 2 to 4 wherein X¹ is CH₂.
 6. A compound according to any of claims 2 to 4 wherein X¹ is S.
 7. A compound according to any of claims 2 to 6 wherein b is
 1. 8. A compound according to any of claims 2 to 6 wherein b is
 2. 9. A compound according to any of claims 2 to 8 wherein a is
 1. 10. A compound according to any of claims 2 to 8 wherein a is 2 and X² is CH₂.
 11. A compound according to any of claims 2 to 10 wherein X³, X⁴ and X⁵ are all N.
 12. A compound according to general formula 9, or a pharmaceutically acceptable salt thereof,

wherein: a is 1 or 2; b is 1 or 2; X¹ is selected from CH₂, S, CF₂, CHF, CH(CH₃), C(CH₃)₂, CH(CN) and O; X³, X⁴ and X⁵ are selected from N and CH, provided that at least two of X³, X⁴ and X⁵ are N; X⁶ is selected from O and NH; R¹ is selected from H and CN; R² is selected from H and alkyl; R³ is selected from H, Cl, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂; R⁴, R⁵, R⁶, R⁷ and R⁸ are independently selected from H, Br, Cl, F, CF₃, alkyl, acyl, OH, O-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NO₂, NH-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂ and CN.
 13. A compound according to claim 12 wherein R¹ is H.
 14. A compound according to claim 12 wherein R¹ is CN.
 15. A compound according to any of claims 12 to 14 wherein X¹ is CH₂.
 16. A compound according to any of claims 12 to 14 wherein X¹ is S.
 17. A compound according to any of claims 12 to 16 wherein b is
 1. 18. A compound according to any of claims 12 to 16 wherein b is
 2. 19. A compound according to any of claims 12 to 18 wherein a is
 1. 20. A compound according to any of claims 12 to 19 wherein X³, X⁴ and X⁵ are all N.
 21. A compound according to general formula 10, or a pharmaceutically acceptable salt thereof,

wherein: a is 0, 1 or 2; b is 1 or 2; X¹ is selected from CH₂, S, CF₂, CHF, CH(CH₃), C(CH₃)₂, CH(CN) and O; X² is selected from CH₂, O and S, provided that if a is 1 then X² is CH₂; X⁷ is selected from O, S, CH₂ and NH; R¹ is selected from H and CN; R⁹ is selected from H and alkyl; R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ are independently selected from H, Br, Cl, F, CF₃, alkyl, acyl, OH, O-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NO₂, NH-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂ and CN is selected from H, Cl, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂.
 22. A compound according to claim 21 wherein R¹ is H.
 23. A compound according to claim 21 wherein R¹ is CN.
 24. A compound according to any of claims 21 to 23 wherein X¹ is CH₂.
 25. A compound according to any of claims 21 to 23 wherein X¹ is S.
 26. A compound according to any of claims 21 to 25 wherein b is
 1. 27. A compound according to any of claims 21 to 25 wherein b is
 2. 28. A compound according to any of claims 21 to 27 wherein a is
 1. 29. A compound according to any of claims 21 to 27 wherein a is 2 and X² is CH₂.
 30. A compound according to general formula 11, or a pharmaceutically acceptable salt thereof,

wherein: a is 1 or 2; b is 1 or 2; X¹ is selected from CH₂, S, CF₂, CHF, CH(CH₃), C(CH₃)₂, CH(CN) and O; X⁷ is selected from O, S, CH₂ and NH; R¹ is selected from H and CN; R⁹ is selected from H and alkyl; R¹⁰, R¹¹, R¹², R¹³ and R¹⁴ are independently selected from H, Br, Cl, F, CF₃, alkyl, acyl, OH, O-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NO₂, NH-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂ and CN is selected from H, Cl, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂.
 31. A compound according to claim 30 wherein R¹ is H.
 32. A compound according to claim 30 wherein R¹ is CN.
 33. A compound according to any of claims 30 to 32 wherein X¹ is CH₂.
 34. A compound according to any of claims 30 to 32 wherein X¹ is S.
 35. A compound according to any of claims 30 to 34 wherein b is
 1. 36. A compound according to any of claims 30 to 34 wherein b is
 2. 37. A compound according to any of claims 30 to 36 wherein a is
 1. 38. A compound according to general formula 12, or a pharmaceutically acceptable salt thereof,

wherein: a is 0, 1 or 2; b is 1 or 2; X¹ is selected from CH₂, S, CF₂, CHF, CH(CH₃), C(CH₃)₂, CH(CN) and O; X² is selected from CH₂, O and S, provided that if a is 1 then X² is CH₂; R¹ is selected from H and CN; R¹⁵ and R¹⁶ are each independently selected from H, alkyl, alkenyl, polyfluoroalkyl, aralkyl, aryl and CH₂-L-R¹⁷; or R¹⁵ and R¹⁶ together are a group according to general formula 5, a group according to general formula 6 or a group according to general formula 7;

R¹⁷ is selected from H, alkyl and aryl; R¹⁸ is selected from H, alkyl, aryl, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂; R¹⁹ is selected from H, alkyl, aryl, F, Cl, Br, CF₃, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂; L is selected from a covalent bond, CH═CH, C≡C and —C₆H₄—; d and e are selected from 0, 1, 2 and 3 such that d+e is 3, 4 or 5; and f is selected from 1, 2 and 3; provided that when R¹⁵ and R¹⁶ are both H and b is 1 then X¹ is not S or CH₂.
 39. A compound according to claim 38 wherein R¹ is H.
 40. A compound according to claim 38 wherein R¹ is CN.
 41. A compound according to any of claims 38 to 40 wherein X¹ is CH₂.
 42. A compound according to any of claims 38 to 40 wherein X¹ is S.
 43. A compound according to any of claims 38 to 42 wherein b is
 1. 44. A compound according to any of claims 38 to 42 wherein b is
 2. 45. A compound according to any of claims 38 to 44 wherein a is
 1. 46. A compound according to any of claims 38 to 44 wherein a is 2 and X² is CH₂.
 47. A compound according to general formula 13, or a pharmaceutically acceptable salt thereof,

wherein: a is 1 or 2; b is 1 or 2; X¹ is selected from CH₂, S, CF₂, CHF, CH(CH₃), C(CH₃)₂, CH(CN) and O; R¹ is selected from H and CN; R¹⁵ and R¹⁶ are each independently selected from H, alkyl, alkenyl, polyfluoroalkyl, aralkyl, aryl and CH₂-L-R¹⁷; or R¹⁵ and R¹⁶ together are a group according to general formula 5, a group according to general formula 6 or a group according to general formula 7;

R¹⁷ is selected from H, alkyl and aryl; R¹⁸ is selected from H, alkyl, aryl, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂; R¹⁹ is selected from H, alkyl, aryl, F, Cl, Br, CF₃, OH, O-alkyl, NH₂, NH-alkyl and N(alkyl)₂; L is selected from a covalent bond, CH═CH, C≡C and —C₆H₄—; d and e are selected from 0, 1, 2 and 3 such that d+e is 3, 4 or 5; and f is selected from 1, 2 and
 3. 48. A compound according to claim 47 wherein R¹ is H.
 49. A compound according to claim 47 wherein R¹ is CN.
 50. A compound according to any of claims 47 to 49 wherein X¹ is CH₂.
 51. A compound according to any of claims 47 to 49 wherein X¹ is S.
 52. A compound according to any of claims 47 to 51 wherein b is
 1. 53. A compound according to any of claims 47 to 51 wherein b is
 2. 54. A compound according to any of claims 47 to 53 wherein a is
 1. 55. A pharmaceutical composition comprising a compound according to any of claims 1 to
 54. 56. A use for a compound according to any of claims 1 to 54, which is as a component in the preparation of a pharmaceutical composition.
 57. A method of treatment of disease in a human or animal subject, comprising a step of administering to the subject a therapeutically active amount of a compound according to any of claims 1 to
 54. 58. A method of treatment according to claim 57 where the disease is caused by dysregulation of a post-proline cleaving proteases or their endogenous substrates.
 59. A method of treatment according to claim 57 where the disease is ameliorated by inhibition of a post-proline cleaving proteases.
 60. A method of treatment according to claim 57 where the disease is caused by dysregulation of a post-proline cleaving proteases or its endogenous substrates which is an intracellular protease.
 61. A composition according to claim 1 or 38 with the proviso that when X¹═S; b=1; R¹═H; G²=H; G¹ is —CH₂—X²—(CH₂)_(a)-G³; a=1, X²═CH₂; G³=NR¹⁵R¹⁶; and one of R¹⁵, R¹⁶═H, the other of R¹⁵, R¹⁶ is not pyridyl, substituted pyridyl, pyrazinyl or substituted pyrazinyl.
 62. A composition according to claim 1, 38, 47 or 60 with the proviso that when b=1, R¹ is H and X¹ is S; G¹=H; G² is —CH₂—(CH₂)_(a)-G³; a=1; G³ is NR¹⁵R¹⁶ and one of R¹⁵ and R¹⁶ is H the other of R¹⁵, R¹⁶ is not pyridyl, substituted pyridyl, pyrazinyl or substituted pyrazinyl.
 63. A composition according to claim 1, 38, 47, 60 or 61 with the proviso that when b=1, R¹ is CN and X¹ is CH₂; G¹=H; G² is —CH₂—(CH₂)_(a)-G³; a=1; G³ is NR¹⁵R¹⁶ and one of R¹⁵ and R¹⁶ is H, the other of R¹⁵, R¹⁶ is not pyridyl, substituted pyridyl, pyrazinyl or substituted pyrazinyl.
 64. A composition according to claim 1, 38, 47, 60, 61 or 62 with the proviso that when G²=H; G¹=-CH2-X²—(CH₂)_(a)-G³; X² is CH₂; a=1; G3=NR¹⁵R¹⁶ and R¹⁵═R¹⁶═H; b is not 2 when X¹ is O or CH₂, and b is not 1 when X¹ is CH₂.
 65. A method of treatment according to claim 57 where the disease is caused by dysregulation of a non-membrane associated post-proline cleaving proteases such as QPP, DPP-8 and DPP-9 enzymes or their endogenous substrates.
 66. A method of treatment according to claim 57 where the disease is ameliorated by inhibition of a non-membrane associated post-proline cleaving proteases such as QPP, DPP-8 and DPP-9 enzymes.
 67. A method according to claim 64 where the compound is a selective inhibitor of non-membrane associated post-proline cleaving proteases. 